|
0
|
1 Id Position Residue Bepipred2 Emini Parker Chou Fosman Karplus Schulz Kolaskar MW IP Hydropathy
|
|
|
2 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 1 V 0.23 0.00 0.00 0.00 0.00 0.00 117.15 5.49 4.20
|
|
|
3 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 2 R 0.27 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
4 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 3 S 0.31 0.23 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
5 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 4 L 0.33 0.45 1.63 1.03 0.98 1.09 131.17 5.52 3.80
|
|
|
6 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 5 N 0.39 0.19 0.84 1.04 0.97 1.07 132.12 5.52 -3.50
|
|
|
7 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 6 C 0.40 0.28 0.84 1.04 0.96 1.07 121.15 5.52 2.50
|
|
|
8 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 7 T 0.41 0.56 1.34 1.04 0.96 1.05 119.12 5.19 -0.70
|
|
|
9 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 8 L 0.42 0.47 3.59 1.16 0.99 1.01 131.17 5.52 3.80
|
|
|
10 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 9 R 0.44 1.50 3.44 1.08 1.03 1.05 174.20 9.75 -4.50
|
|
|
11 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 10 D 0.45 1.80 4.10 1.05 1.07 0.99 133.10 3.80 -3.50
|
|
|
12 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 11 S 0.46 4.37 4.17 1.06 1.11 0.99 105.09 5.24 -0.80
|
|
|
13 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 12 Q 0.45 2.99 6.41 1.18 1.12 0.96 146.15 5.52 -3.50
|
|
|
14 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 13 Q 0.45 1.48 4.50 1.13 1.12 1.01 146.15 5.52 -3.50
|
|
|
15 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 14 K 0.43 0.82 2.54 0.99 1.08 1.09 146.19 8.75 -3.90
|
|
|
16 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 15 S 0.43 0.47 1.01 0.87 1.03 1.06 105.09 5.24 -0.80
|
|
|
17 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 16 L 0.43 0.36 1.09 0.93 0.99 1.06 131.17 5.52 3.80
|
|
|
18 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 17 V 0.42 0.18 1.04 1.02 0.97 1.04 117.15 5.49 4.20
|
|
|
19 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 18 M 0.42 0.21 0.53 1.09 0.98 1.06 149.21 5.28 1.90
|
|
|
20 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 19 S 0.41 0.39 -0.67 1.05 1.01 1.08 105.09 5.24 -0.80
|
|
|
21 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 20 G 0.39 0.92 1.76 1.07 1.03 1.02 75.07 5.52 -0.40
|
|
|
22 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 21 P 0.41 0.76 0.97 1.08 1.03 1.01 115.13 5.96 -1.60
|
|
|
23 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 22 Y 0.42 1.14 2.39 1.14 1.01 1.02 181.19 5.52 -1.30
|
|
|
24 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 23 E 0.43 1.16 1.76 1.03 0.99 1.03 147.13 4.00 -3.50
|
|
|
25 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 24 L 0.43 0.62 -0.37 0.89 0.98 1.08 131.17 5.52 3.80
|
|
|
26 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 25 K 0.43 0.54 -0.37 0.81 0.97 1.09 146.19 8.75 -3.90
|
|
|
27 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 26 A 0.44 0.26 -1.41 0.73 0.96 1.10 89.09 5.57 1.80
|
|
|
28 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 27 L 0.46 0.54 -1.67 0.77 0.95 1.12 131.17 5.52 3.80
|
|
|
29 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 28 H 0.48 0.27 0.46 0.91 0.96 1.07 155.16 6.74 -3.20
|
|
|
30 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 29 L 0.52 0.46 0.50 0.90 0.99 1.08 131.17 5.52 3.80
|
|
|
31 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 30 Q 0.54 0.92 1.63 1.02 1.03 1.05 146.15 5.52 -3.50
|
|
|
32 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 31 G 0.58 0.67 2.34 1.02 1.07 0.99 75.07 5.52 -0.40
|
|
|
33 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 32 Q 0.59 1.41 3.16 0.99 1.08 0.96 146.15 5.52 -3.50
|
|
|
34 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 33 D 0.61 1.41 5.33 1.04 1.08 0.92 133.10 3.80 -3.50
|
|
|
35 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 34 M 0.60 2.47 5.33 1.04 1.06 0.92 149.21 5.28 1.90
|
|
|
36 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 35 E 0.58 1.06 3.99 0.89 1.05 1.00 147.13 4.00 -3.50
|
|
|
37 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 36 Q 0.54 0.47 2.60 0.82 1.04 1.05 146.15 5.52 -3.50
|
|
|
38 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 37 Q 0.51 0.41 -0.14 0.70 1.01 1.08 146.15 5.52 -3.50
|
|
|
39 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 38 V 0.47 0.32 1.39 0.82 0.98 1.11 117.15 5.49 4.20
|
|
|
40 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 39 V 0.46 0.18 -0.33 0.80 0.95 1.10 117.15 5.49 4.20
|
|
|
41 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 40 F 0.44 0.14 -0.26 0.86 0.93 1.10 165.19 5.52 2.80
|
|
|
42 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 41 S 0.42 0.16 -2.43 0.81 0.92 1.11 105.09 5.24 -0.80
|
|
|
43 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 42 M 0.41 0.16 -2.43 0.81 0.93 1.11 149.21 5.28 1.90
|
|
|
44 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 43 S 0.44 0.33 -1.04 0.88 0.93 1.06 105.09 5.24 -0.80
|
|
|
45 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 44 F 0.46 0.24 1.09 1.01 0.95 1.03 165.19 5.52 2.80
|
|
|
46 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 45 V 0.50 0.43 1.27 0.92 0.98 1.01 117.15 5.49 4.20
|
|
|
47 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 46 Q 0.53 0.55 2.99 0.94 1.02 1.01 146.15 5.52 -3.50
|
|
|
48 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 47 G 0.55 0.85 2.99 0.94 1.07 1.01 75.07 5.52 -0.40
|
|
|
49 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 48 E 0.56 1.84 5.30 1.07 1.10 0.97 147.13 4.00 -3.50
|
|
|
50 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 49 E 0.58 1.78 7.26 1.21 1.11 0.89 147.13 4.00 -3.50
|
|
|
51 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 50 S 0.58 3.59 7.21 1.21 1.11 0.88 105.09 5.24 -0.80
|
|
|
52 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 51 N 0.56 1.45 5.26 1.06 1.10 0.92 132.12 5.52 -3.50
|
|
|
53 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 52 D 0.52 1.30 4.44 1.17 1.07 0.95 133.10 3.80 -3.50
|
|
|
54 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 53 K 0.49 0.72 2.80 1.14 1.04 1.03 146.19 8.75 -3.90
|
|
|
55 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 54 I 0.45 0.45 2.17 1.03 1.00 1.03 131.17 5.52 4.50
|
|
|
56 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 55 P 0.42 0.22 -0.14 0.89 0.97 1.10 115.13 5.96 -1.60
|
|
|
57 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 56 V 0.39 0.11 -0.76 0.90 0.94 1.10 117.15 5.49 4.20
|
|
|
58 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 57 A 0.39 0.13 -2.89 0.84 0.93 1.15 89.09 5.57 1.80
|
|
|
59 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 58 L 0.39 0.17 -0.93 0.92 0.94 1.12 131.17 5.52 3.80
|
|
|
60 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 59 G 0.39 0.39 -0.11 0.81 0.97 1.09 75.07 5.52 -0.40
|
|
|
61 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 60 L 0.41 0.78 1.23 0.88 1.00 1.02 131.17 5.52 3.80
|
|
|
62 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 61 K 0.43 1.51 1.93 1.01 1.03 0.98 146.19 8.75 -3.90
|
|
|
63 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 62 E 0.44 1.26 1.93 1.01 1.05 0.98 147.13 4.00 -3.50
|
|
|
64 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 63 K 0.44 2.39 0.84 0.95 1.04 1.02 146.19 8.75 -3.90
|
|
|
65 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 64 N 0.44 0.99 0.84 0.95 1.01 1.02 132.12 5.52 -3.50
|
|
|
66 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 65 L 0.44 0.76 0.96 1.01 0.97 1.03 131.17 5.52 3.80
|
|
|
67 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 66 Y 0.43 0.20 0.04 1.07 0.93 1.11 181.19 5.52 -1.30
|
|
|
68 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 67 L 0.43 0.09 -1.30 1.00 0.92 1.18 131.17 5.52 3.80
|
|
|
69 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 68 S 0.43 0.09 -3.61 0.86 0.91 1.25 105.09 5.24 -0.80
|
|
|
70 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 69 C 0.43 0.12 -1.49 0.92 0.92 1.20 121.15 5.52 2.50
|
|
|
71 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 70 V 0.43 0.24 0.21 0.97 0.95 1.16 117.15 5.49 4.20
|
|
|
72 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 71 L 0.44 0.30 2.96 1.09 0.98 1.10 131.17 5.52 3.80
|
|
|
73 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 72 K 0.45 1.14 2.84 1.03 1.01 1.09 146.19 8.75 -3.90
|
|
|
74 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 73 D 0.46 2.37 2.94 1.08 1.03 1.04 133.10 3.80 -3.50
|
|
|
75 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 74 D 0.45 4.14 4.21 1.14 1.05 0.97 133.10 3.80 -3.50
|
|
|
76 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 75 K 0.45 1.71 4.21 1.14 1.05 0.97 146.19 8.75 -3.90
|
|
|
77 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 76 P 0.44 1.77 4.26 1.14 1.04 0.99 115.13 5.96 -1.60
|
|
|
78 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 77 T 0.45 0.87 1.51 1.02 1.01 1.04 119.12 5.19 -0.70
|
|
|
79 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 78 L 0.46 0.76 1.20 0.91 0.99 1.04 131.17 5.52 3.80
|
|
|
80 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 79 Q 0.48 0.66 1.31 0.97 0.98 1.05 146.15 5.52 -3.50
|
|
|
81 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 80 L 0.49 0.34 0.49 0.83 0.98 1.10 131.17 5.52 3.80
|
|
|
82 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 81 E 0.50 0.68 1.17 0.90 1.00 1.09 147.13 4.00 -3.50
|
|
|
83 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 82 S 0.52 0.61 2.79 1.03 1.02 1.06 105.09 5.24 -0.80
|
|
|
84 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 83 V 0.55 1.48 2.74 1.04 1.04 1.05 117.15 5.49 4.20
|
|
|
85 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 84 D 0.56 1.37 5.06 1.17 1.05 0.98 133.10 3.80 -3.50
|
|
|
86 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 85 P 0.59 1.61 3.67 1.23 1.05 1.03 115.13 5.96 -1.60
|
|
|
87 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 86 K 0.59 3.35 3.04 1.24 1.05 1.03 146.19 8.75 -3.90
|
|
|
88 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 87 N 0.59 4.01 4.39 1.32 1.04 0.97 132.12 5.52 -3.50
|
|
|
89 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 88 Y 0.58 5.18 3.77 1.25 1.04 0.98 181.19 5.52 -1.30
|
|
|
90 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 89 P 0.56 5.18 4.29 1.18 1.05 0.96 115.13 5.96 -1.60
|
|
|
91 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 90 K 0.55 3.19 2.87 1.12 1.06 0.95 146.19 8.75 -3.90
|
|
|
92 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 91 K 0.53 3.52 2.99 1.00 1.06 0.96 146.19 8.75 -3.90
|
|
|
93 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 92 K 0.52 4.56 4.07 0.99 1.06 0.92 146.19 8.75 -3.90
|
|
|
94 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 93 M 0.51 4.46 4.37 0.90 1.04 0.90 149.21 5.28 1.90
|
|
|
95 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 94 E 0.49 1.93 2.24 0.85 1.03 0.92 147.13 4.00 -3.50
|
|
|
96 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 95 K 0.48 0.72 0.90 0.77 1.02 0.98 146.19 8.75 -3.90
|
|
|
97 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 96 R 0.46 0.63 -1.23 0.71 0.99 1.01 174.20 9.75 -4.50
|
|
|
98 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 97 F 0.45 0.58 0.37 0.85 0.97 1.00 165.19 5.52 2.80
|
|
|
99 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 98 V 0.46 0.58 0.07 0.89 0.96 1.01 117.15 5.49 4.20
|
|
|
100 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 99 F 0.47 0.21 -1.89 0.81 0.96 1.04 165.19 5.52 2.80
|
|
|
101 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 100 N 0.49 0.42 -1.37 0.78 0.98 1.04 132.12 5.52 -3.50
|
|
|
102 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 101 K 0.50 0.39 -1.20 0.76 1.00 1.05 146.19 8.75 -3.90
|
|
|
103 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 102 I 0.51 0.73 0.33 0.92 1.00 0.96 131.17 5.52 4.50
|
|
|
104 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 103 E 0.54 0.73 2.64 1.05 1.00 0.92 147.13 4.00 -3.50
|
|
|
105 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 104 I 0.54 0.73 2.46 0.97 1.01 0.94 131.17 5.52 4.50
|
|
|
106 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 105 N 0.56 0.86 0.33 0.91 1.02 0.98 132.12 5.52 -3.50
|
|
|
107 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 106 N 0.54 0.86 2.59 0.95 1.03 0.94 132.12 5.52 -3.50
|
|
|
108 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 107 K 0.54 1.06 0.16 0.93 1.02 0.98 146.19 8.75 -3.90
|
|
|
109 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 108 L 0.51 1.15 2.41 0.97 1.00 0.93 131.17 5.52 3.80
|
|
|
110 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 109 E 0.49 0.95 2.34 0.95 0.99 0.97 147.13 4.00 -3.50
|
|
|
111 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 110 F 0.48 0.48 1.64 0.82 0.99 1.01 165.19 5.52 2.80
|
|
|
112 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 111 E 0.47 1.01 1.69 0.82 0.99 1.02 147.13 4.00 -3.50
|
|
|
113 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 112 S 0.45 0.51 1.69 0.82 0.99 1.00 105.09 5.24 -0.80
|
|
|
114 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 113 A 0.45 0.90 0.87 0.93 0.99 1.03 89.09 5.57 1.80
|
|
|
115 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 114 Q 0.42 0.84 3.19 1.07 0.99 0.98 146.15 5.52 -3.50
|
|
|
116 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 115 F 0.42 0.66 0.64 1.10 0.98 0.99 165.19 5.52 2.80
|
|
|
117 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 116 P 0.39 1.02 -0.56 1.06 0.98 1.01 115.13 5.96 -1.60
|
|
|
118 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 117 N 0.39 0.41 -2.00 1.03 0.96 1.02 132.12 5.52 -3.50
|
|
|
119 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 118 W 0.38 0.64 -1.93 1.10 0.95 1.02 204.23 5.52 -0.90
|
|
|
120 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 119 Y 0.37 0.60 0.13 1.15 0.94 1.00 181.19 5.52 -1.30
|
|
|
121 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 120 I 0.38 0.50 0.76 1.14 0.96 0.99 131.17 5.52 4.50
|
|
|
122 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 121 S 0.39 0.82 0.61 1.05 1.00 1.02 105.09 5.24 -0.80
|
|
|
123 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 122 T 0.41 0.53 2.34 1.01 1.04 1.05 119.12 5.19 -0.70
|
|
|
124 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 123 S 0.43 1.31 3.73 0.95 1.07 1.00 105.09 5.24 -0.80
|
|
|
125 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 124 Q 0.45 1.57 5.87 1.11 1.06 0.95 146.15 5.52 -3.50
|
|
|
126 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 125 A 0.47 1.07 4.34 0.99 1.05 0.92 89.09 5.57 1.80
|
|
|
127 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 126 E 0.48 1.24 3.90 1.07 1.02 0.94 147.13 4.00 -3.50
|
|
|
128 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 127 N 0.49 0.53 2.44 0.94 0.99 1.00 132.12 5.52 -3.50
|
|
|
129 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 128 M 0.48 0.46 0.27 0.88 0.97 1.01 149.21 5.28 1.90
|
|
|
130 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 129 P 0.45 0.22 -1.34 0.87 0.95 1.03 115.13 5.96 -1.60
|
|
|
131 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 130 V 0.45 0.13 -1.64 0.99 0.94 1.04 117.15 5.49 4.20
|
|
|
132 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 131 F 0.45 0.13 -1.83 0.99 0.96 1.05 165.19 5.52 2.80
|
|
|
133 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 132 L 0.46 0.09 -0.41 1.13 1.00 1.06 131.17 5.52 3.80
|
|
|
134 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 133 G 0.47 0.11 0.10 1.13 1.04 1.03 75.07 5.52 -0.40
|
|
|
135 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 134 G 0.49 0.23 1.49 1.20 1.09 0.98 75.07 5.52 -0.40
|
|
|
136 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 135 G 0.51 0.46 4.23 1.32 1.12 0.95 75.07 5.52 -0.40
|
|
|
137 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 136 G 0.52 0.33 4.40 1.31 1.12 0.93 75.07 5.52 -0.40
|
|
|
138 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 137 Q 0.54 0.48 4.33 1.22 1.11 0.94 146.15 5.52 -3.50
|
|
|
139 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 138 D 0.54 0.80 4.94 1.21 1.09 0.94 133.10 3.80 -3.50
|
|
|
140 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 139 I 0.52 0.70 2.81 1.07 1.06 0.97 131.17 5.52 4.50
|
|
|
141 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 140 T 0.49 0.59 2.74 0.98 1.04 0.97 119.12 5.19 -0.70
|
|
|
142 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 141 D 0.49 0.35 1.29 0.93 1.01 0.95 133.10 3.80 -3.50
|
|
|
143 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 142 F 0.48 0.86 0.71 0.86 0.98 0.97 165.19 5.52 2.80
|
|
|
144 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 143 T 0.47 0.52 0.54 0.88 0.95 0.96 119.12 5.19 -0.70
|
|
|
145 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 144 M 0.47 0.23 -0.73 0.81 0.93 1.03 149.21 5.28 1.90
|
|
|
146 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 145 Q 0.47 0.35 -1.23 0.81 0.93 1.05 146.15 5.52 -3.50
|
|
|
147 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 146 F 0.41 0.33 1.01 0.93 0.00 1.04 165.19 5.52 2.80
|
|
|
148 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 147 V 0.38 0.00 0.00 0.00 0.00 0.00 117.15 5.49 4.20
|
|
|
149 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 148 S 0.33 0.00 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
150 5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta 149 S 0.29 0.00 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
151 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 1 V 0.27 0.00 0.00 0.00 0.00 0.00 117.15 5.49 4.20
|
|
|
152 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 2 E 0.33 0.00 0.00 0.00 0.00 0.00 147.13 4.00 -3.50
|
|
|
153 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 3 C 0.39 0.34 0.00 0.00 0.00 0.00 121.15 5.52 2.50
|
|
|
154 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 4 D 0.45 0.71 2.13 1.06 0.96 1.10 133.10 3.80 -3.50
|
|
|
155 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 5 F 0.52 0.34 1.34 1.08 0.98 1.08 165.19 5.52 2.80
|
|
|
156 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 6 S 0.53 0.52 -1.09 1.05 1.00 1.13 105.09 5.24 -0.80
|
|
|
157 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 7 P 0.54 0.42 -0.36 1.09 1.01 1.08 115.13 5.96 -1.60
|
|
|
158 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 8 L 0.54 0.48 -0.97 1.10 1.02 1.08 131.17 5.52 3.80
|
|
|
159 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 9 L 0.53 0.52 1.09 1.15 1.03 1.05 131.17 5.52 3.80
|
|
|
160 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 10 S 0.53 0.52 0.46 1.17 1.04 1.06 105.09 5.24 -0.80
|
|
|
161 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 11 G 0.53 0.97 0.46 1.17 1.06 1.06 75.07 5.52 -0.40
|
|
|
162 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 12 T 0.52 2.03 2.63 1.22 1.07 1.03 119.12 5.19 -0.70
|
|
|
163 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 13 P 0.52 1.12 3.41 1.21 1.06 1.05 115.13 5.96 -1.60
|
|
|
164 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 14 P 0.51 1.78 2.21 1.17 1.03 1.07 115.13 5.96 -1.60
|
|
|
165 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 15 Q 0.50 1.98 2.40 1.17 1.00 1.05 146.15 5.52 -3.50
|
|
|
166 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 16 V 0.50 1.11 0.34 1.12 0.97 1.08 117.15 5.49 4.20
|
|
|
167 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 17 Y 0.50 1.44 0.86 1.04 0.96 1.06 181.19 5.52 -1.30
|
|
|
168 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 18 N 0.51 1.62 1.16 0.96 0.96 1.03 132.12 5.52 -3.50
|
|
|
169 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 19 F 0.51 1.80 -1.01 0.91 0.97 1.07 165.19 5.52 2.80
|
|
|
170 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 20 K 0.49 0.85 -1.01 0.91 0.99 1.07 146.19 8.75 -3.90
|
|
|
171 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 21 R 0.49 0.46 -2.06 0.83 0.99 1.06 174.20 9.75 -4.50
|
|
|
172 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 22 L 0.50 0.77 -2.31 0.74 0.98 1.08 131.17 5.52 3.80
|
|
|
173 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 23 V 0.50 0.62 0.00 0.88 0.97 1.03 117.15 5.49 4.20
|
|
|
174 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 24 F 0.52 0.17 -0.61 0.91 0.97 1.10 165.19 5.52 2.80
|
|
|
175 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 25 T 0.53 0.33 -0.21 0.99 0.97 1.09 119.12 5.19 -0.70
|
|
|
176 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 26 N 0.54 0.69 0.83 1.07 0.98 1.07 132.12 5.52 -3.50
|
|
|
177 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 27 C 0.54 1.29 2.36 1.22 0.97 0.99 121.15 5.52 2.50
|
|
|
178 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 28 N 0.55 0.74 2.36 1.22 0.96 1.01 132.12 5.52 -3.50
|
|
|
179 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 29 Y 0.57 0.66 2.36 1.22 0.96 1.01 181.19 5.52 -1.30
|
|
|
180 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 30 N 0.56 2.47 2.17 1.14 0.97 1.03 132.12 5.52 -3.50
|
|
|
181 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 31 L 0.56 1.27 0.66 1.06 0.99 1.01 131.17 5.52 3.80
|
|
|
182 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 32 T 0.56 0.67 -1.66 0.92 1.00 1.08 119.12 5.19 -0.70
|
|
|
183 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 33 K 0.55 0.56 -0.46 0.96 1.00 1.05 146.19 8.75 -3.90
|
|
|
184 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 34 L 0.55 0.56 -2.77 0.82 0.99 1.12 131.17 5.52 3.80
|
|
|
185 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 35 L 0.55 0.33 -2.77 0.82 0.97 1.10 131.17 5.52 3.80
|
|
|
186 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 36 S 0.56 0.22 -2.59 0.89 0.95 1.11 105.09 5.24 -0.80
|
|
|
187 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 37 L 0.57 0.20 -3.93 0.82 0.94 1.18 131.17 5.52 3.80
|
|
|
188 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 38 F 0.57 0.39 -1.61 0.96 0.94 1.11 165.19 5.52 2.80
|
|
|
189 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 39 S 0.58 0.49 1.13 1.08 0.96 1.06 105.09 5.24 -0.80
|
|
|
190 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 40 V 0.58 0.51 -1.11 0.96 0.98 1.07 117.15 5.49 4.20
|
|
|
191 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 41 N 0.57 0.85 0.94 1.02 0.99 1.02 132.12 5.52 -3.50
|
|
|
192 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 42 D 0.58 0.34 2.46 1.10 0.99 1.06 133.10 3.80 -3.50
|
|
|
193 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 43 F 0.57 0.62 2.46 1.10 0.98 1.06 165.19 5.52 2.80
|
|
|
194 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 44 T 0.56 0.66 3.84 1.17 0.98 1.01 119.12 5.19 -0.70
|
|
|
195 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 45 C 0.57 0.28 1.70 1.01 0.99 1.07 121.15 5.52 2.50
|
|
|
196 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 46 S 0.55 0.43 1.20 1.01 1.00 1.09 105.09 5.24 -0.80
|
|
|
197 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 47 Q 0.54 0.46 2.81 1.14 1.02 1.08 146.15 5.52 -3.50
|
|
|
198 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 48 I 0.54 0.87 2.37 1.10 1.03 1.10 131.17 5.52 4.50
|
|
|
199 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 49 S 0.52 0.66 2.47 1.02 1.02 1.05 105.09 5.24 -0.80
|
|
|
200 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 50 P 0.51 0.27 0.40 0.88 1.00 1.07 115.13 5.96 -1.60
|
|
|
201 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 51 A 0.51 0.38 -0.16 0.84 0.97 1.08 89.09 5.57 1.80
|
|
|
202 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 52 A 0.51 0.38 1.91 0.98 0.95 1.06 89.09 5.57 1.80
|
|
|
203 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 53 I 0.52 0.40 1.99 0.99 0.94 1.03 131.17 5.52 4.50
|
|
|
204 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 54 A 0.53 0.21 1.89 0.95 0.95 1.08 89.09 5.57 1.80
|
|
|
205 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 55 S 0.55 0.33 1.31 1.02 0.96 1.09 105.09 5.24 -0.80
|
|
|
206 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 56 N 0.55 0.63 1.94 1.13 0.97 1.08 132.12 5.52 -3.50
|
|
|
207 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 57 C 0.56 0.83 4.01 1.26 0.97 1.06 121.15 5.52 2.50
|
|
|
208 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 58 Y 0.57 0.51 2.40 1.25 0.98 1.09 181.19 5.52 -1.30
|
|
|
209 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 59 S 0.58 0.22 0.33 1.12 0.98 1.11 105.09 5.24 -0.80
|
|
|
210 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 60 S 0.57 0.34 -1.99 0.98 0.98 1.18 105.09 5.24 -0.80
|
|
|
211 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 61 L 0.56 0.37 -0.76 1.02 0.97 1.10 131.17 5.52 3.80
|
|
|
212 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 62 I 0.55 0.43 -0.76 1.02 0.95 1.10 131.17 5.52 4.50
|
|
|
213 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 63 L 0.54 0.28 -3.00 0.90 0.94 1.11 131.17 5.52 3.80
|
|
|
214 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 64 D 0.53 0.45 -3.00 0.90 0.93 1.11 133.10 3.80 -3.50
|
|
|
215 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 65 Y 0.52 1.00 -1.96 0.98 0.93 1.10 181.19 5.52 -1.30
|
|
|
216 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 66 F 0.52 1.88 -0.51 1.13 0.93 1.09 165.19 5.52 2.80
|
|
|
217 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 67 S 0.53 0.93 -0.51 1.13 0.93 1.09 105.09 5.24 -0.80
|
|
|
218 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 68 Y 0.54 0.80 -1.01 1.12 0.94 1.11 181.19 5.52 -1.30
|
|
|
219 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 69 P 0.55 0.91 -1.34 1.04 0.94 1.06 115.13 5.96 -1.60
|
|
|
220 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 70 L 0.56 1.36 0.79 1.10 0.95 1.04 131.17 5.52 3.80
|
|
|
221 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 71 S 0.57 1.16 0.79 1.10 0.97 1.04 105.09 5.24 -0.80
|
|
|
222 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 72 M 0.58 1.25 2.49 1.15 1.01 0.99 149.21 5.28 1.90
|
|
|
223 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 73 K 0.59 1.25 0.87 1.02 1.04 1.02 146.19 8.75 -3.90
|
|
|
224 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 74 S 0.61 1.25 3.11 1.14 1.05 0.99 105.09 5.24 -0.80
|
|
|
225 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 75 D 0.63 0.94 1.66 1.00 1.04 1.04 133.10 3.80 -3.50
|
|
|
226 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 76 L 0.63 0.63 3.19 1.12 1.02 1.07 131.17 5.52 3.80
|
|
|
227 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 77 S 0.62 0.63 3.30 1.18 1.00 1.08 105.09 5.24 -0.80
|
|
|
228 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 78 V 0.61 0.38 2.67 1.07 1.00 1.09 117.15 5.49 4.20
|
|
|
229 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 79 S 0.59 0.46 2.06 1.09 1.01 1.09 105.09 5.24 -0.80
|
|
|
230 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 80 S 0.58 0.53 3.67 1.22 1.03 1.06 105.09 5.24 -0.80
|
|
|
231 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 81 A 0.58 0.50 1.60 1.08 1.04 1.08 89.09 5.57 1.80
|
|
|
232 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 82 G 0.57 0.50 3.06 1.21 1.05 1.03 75.07 5.52 -0.40
|
|
|
233 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 83 P 0.56 0.64 2.99 1.15 1.05 1.03 115.13 5.96 -1.60
|
|
|
234 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 84 I 0.55 0.55 0.74 1.03 1.03 1.04 131.17 5.52 4.50
|
|
|
235 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 85 S 0.55 0.90 1.44 1.16 1.02 1.00 105.09 5.24 -0.80
|
|
|
236 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 86 Q 0.56 0.91 0.36 1.10 1.00 1.04 146.15 5.52 -3.50
|
|
|
237 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 87 F 0.57 2.59 0.87 1.03 0.98 1.02 165.19 5.52 2.80
|
|
|
238 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 88 N 0.58 3.35 2.87 1.10 0.99 1.00 132.12 5.52 -3.50
|
|
|
239 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 89 Y 0.58 2.59 2.87 1.10 1.01 1.00 181.19 5.52 -1.30
|
|
|
240 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 90 K 0.58 2.59 0.70 1.05 1.03 1.01 146.19 8.75 -3.90
|
|
|
241 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 91 Q 0.58 2.16 2.94 1.16 1.05 1.00 146.15 5.52 -3.50
|
|
|
242 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 92 S 0.57 2.22 2.94 1.16 1.05 1.00 105.09 5.24 -0.80
|
|
|
243 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 93 F 0.57 1.71 3.51 1.22 1.04 0.99 165.19 5.52 2.80
|
|
|
244 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 94 S 0.57 1.43 3.44 1.21 1.05 0.98 105.09 5.24 -0.80
|
|
|
245 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 95 N 0.56 0.57 2.79 1.24 1.04 1.04 132.12 5.52 -3.50
|
|
|
246 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 96 P 0.54 0.54 0.54 1.12 1.03 1.07 115.13 5.96 -1.60
|
|
|
247 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 97 T 0.53 0.28 0.71 1.10 1.00 1.08 119.12 5.19 -0.70
|
|
|
248 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 98 C 0.52 0.15 -1.53 0.98 0.96 1.12 121.15 5.52 2.50
|
|
|
249 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 99 L 0.51 0.10 -2.23 0.85 0.93 1.16 131.17 5.52 3.80
|
|
|
250 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 100 I 0.50 0.10 -1.79 0.77 0.92 1.14 131.17 5.52 4.50
|
|
|
251 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 101 L 0.51 0.13 -3.06 0.71 0.92 1.20 131.17 5.52 3.80
|
|
|
252 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 102 A 0.51 0.25 -2.96 0.76 0.93 1.15 89.09 5.57 1.80
|
|
|
253 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 103 T 0.52 0.48 -1.34 0.81 0.94 1.13 119.12 5.19 -0.70
|
|
|
254 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 104 V 0.51 0.94 0.80 0.96 0.95 1.08 117.15 5.49 4.20
|
|
|
255 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 105 P 0.52 0.76 0.80 0.96 0.95 1.08 115.13 5.96 -1.60
|
|
|
256 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 106 H 0.53 0.76 1.24 1.01 0.96 1.06 155.16 6.74 -3.20
|
|
|
257 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 107 N 0.54 1.49 1.24 1.01 0.97 1.06 132.12 5.52 -3.50
|
|
|
258 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 108 L 0.53 0.67 0.63 1.00 0.99 1.02 131.17 5.52 3.80
|
|
|
259 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 109 T 0.54 0.72 1.07 0.92 1.01 1.00 119.12 5.19 -0.70
|
|
|
260 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 110 T 0.53 0.89 1.59 0.93 1.03 0.98 119.12 5.19 -0.70
|
|
|
261 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 111 I 0.52 1.67 0.89 0.92 1.04 1.02 131.17 5.52 4.50
|
|
|
262 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 112 T 0.50 0.95 0.89 0.92 1.05 1.02 119.12 5.19 -0.70
|
|
|
263 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 113 K 0.51 1.32 0.96 0.93 1.05 1.02 146.19 8.75 -3.90
|
|
|
264 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 114 P 0.50 2.95 -0.06 0.96 1.04 1.06 115.13 5.96 -1.60
|
|
|
265 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 115 L 0.50 2.74 2.01 1.09 1.02 1.04 131.17 5.52 3.80
|
|
|
266 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 116 K 0.51 2.15 1.00 1.12 1.00 1.07 146.19 8.75 -3.90
|
|
|
267 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 117 Y 0.52 0.97 -0.96 1.04 0.97 1.10 181.19 5.52 -1.30
|
|
|
268 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 118 S 0.53 1.90 -0.26 1.05 0.95 1.06 105.09 5.24 -0.80
|
|
|
269 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 119 Y 0.53 1.90 1.87 1.11 0.95 1.02 181.19 5.52 -1.30
|
|
|
270 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 120 I 0.53 0.65 1.26 1.13 0.96 1.09 131.17 5.52 4.50
|
|
|
271 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 121 N 0.55 0.65 2.46 1.18 0.98 1.06 132.12 5.52 -3.50
|
|
|
272 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 122 K 0.55 0.81 2.13 1.11 1.00 1.05 146.19 8.75 -3.90
|
|
|
273 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 123 C 0.56 1.00 1.09 1.03 1.01 1.04 121.15 5.52 2.50
|
|
|
274 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 124 S 0.56 0.51 0.91 1.05 1.01 1.05 105.09 5.24 -0.80
|
|
|
275 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 125 R 0.56 0.34 0.84 1.03 1.00 1.08 174.20 9.75 -4.50
|
|
|
276 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 126 F 0.56 1.07 1.46 1.09 0.99 1.07 165.19 5.52 2.80
|
|
|
277 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 127 L 0.56 1.34 2.69 1.13 1.00 1.00 131.17 5.52 3.80
|
|
|
278 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 128 S 0.56 1.34 2.36 1.06 1.01 0.98 105.09 5.24 -0.80
|
|
|
279 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 129 D 0.56 2.23 2.50 1.06 1.02 0.98 133.10 3.80 -3.50
|
|
|
280 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 130 D 0.54 4.68 4.93 1.08 1.04 0.95 133.10 3.80 -3.50
|
|
|
281 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 131 R 0.53 2.59 5.71 1.07 1.04 0.97 174.20 9.75 -4.50
|
|
|
282 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 132 T 0.53 2.40 5.09 1.08 1.04 0.97 119.12 5.19 -0.70
|
|
|
283 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 133 E 0.53 2.49 4.51 1.02 1.04 0.99 147.13 4.00 -3.50
|
|
|
284 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 134 V 0.53 1.05 1.77 0.89 1.03 1.05 117.15 5.49 4.20
|
|
|
285 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 135 P 0.53 0.54 0.64 0.83 1.02 1.12 115.13 5.96 -1.60
|
|
|
286 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 136 Q 0.53 0.50 0.90 0.91 1.00 1.10 146.15 5.52 -3.50
|
|
|
287 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 137 L 0.55 0.68 0.09 0.90 0.99 1.13 131.17 5.52 3.80
|
|
|
288 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 138 V 0.57 0.71 1.61 1.05 0.98 1.05 117.15 5.49 4.20
|
|
|
289 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 139 N 0.59 0.71 2.17 0.98 0.98 1.04 132.12 5.52 -3.50
|
|
|
290 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 140 A 0.61 1.35 1.04 1.00 0.99 1.06 89.09 5.57 1.80
|
|
|
291 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 141 N 0.60 2.43 3.29 1.12 1.00 1.03 132.12 5.52 -3.50
|
|
|
292 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 142 Q 0.60 2.34 4.11 1.26 1.01 0.98 146.15 5.52 -3.50
|
|
|
293 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 143 Y 0.60 1.24 3.31 1.21 1.01 1.07 181.19 5.52 -1.30
|
|
|
294 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 144 S 0.59 0.57 2.49 1.19 1.00 1.12 105.09 5.24 -0.80
|
|
|
295 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 145 P 0.58 0.44 2.41 1.17 0.99 1.15 115.13 5.96 -1.60
|
|
|
296 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 146 C 0.55 0.20 0.41 1.10 0.96 1.17 121.15 5.52 2.50
|
|
|
297 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 147 V 0.52 0.11 0.16 1.01 0.94 1.20 117.15 5.49 4.20
|
|
|
298 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 148 S 0.51 0.11 -0.47 1.02 0.93 1.21 105.09 5.24 -0.80
|
|
|
299 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 149 I 0.51 0.27 0.16 1.01 0.95 1.20 131.17 5.52 4.50
|
|
|
300 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 150 V 0.51 0.53 0.70 0.97 0.99 1.13 117.15 5.49 4.20
|
|
|
301 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 151 P 0.51 0.30 0.70 0.97 1.02 1.13 115.13 5.96 -1.60
|
|
|
302 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 152 S 0.51 0.44 -1.66 0.91 1.04 1.11 105.09 5.24 -0.80
|
|
|
303 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 153 T 0.51 1.03 0.60 0.94 1.03 1.07 119.12 5.19 -0.70
|
|
|
304 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 154 V 0.51 1.12 2.56 1.08 1.01 1.00 117.15 5.49 4.20
|
|
|
305 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 155 W 0.52 0.83 3.07 1.09 1.00 0.97 204.23 5.52 -0.90
|
|
|
306 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 156 E 0.52 0.95 3.57 1.09 1.02 0.95 147.13 4.00 -3.50
|
|
|
307 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 157 D 0.52 2.02 2.56 1.12 1.03 0.98 133.10 3.80 -3.50
|
|
|
308 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 158 G 0.51 3.00 2.81 1.21 1.04 0.95 75.07 5.52 -0.40
|
|
|
309 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 159 D 0.52 3.40 4.84 1.21 1.04 0.95 133.10 3.80 -3.50
|
|
|
310 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 160 Y 0.52 4.07 4.54 1.25 1.02 0.96 181.19 5.52 -1.30
|
|
|
311 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 161 Y 0.52 7.12 3.97 1.18 1.01 0.98 181.19 5.52 -1.30
|
|
|
312 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 162 R 0.53 3.52 1.84 1.04 1.01 1.04 174.20 9.75 -4.50
|
|
|
313 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 163 K 0.53 3.01 1.34 1.03 1.02 1.06 146.19 8.75 -3.90
|
|
|
314 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 164 Q 0.53 2.97 1.91 1.09 1.03 1.04 146.15 5.52 -3.50
|
|
|
315 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 165 L 0.55 1.25 0.87 1.01 1.03 1.06 131.17 5.52 3.80
|
|
|
316 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 166 S 0.55 1.08 1.39 0.98 1.03 1.05 105.09 5.24 -0.80
|
|
|
317 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 167 P 0.56 0.62 1.39 1.06 1.04 1.05 115.13 5.96 -1.60
|
|
|
318 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 168 L 0.55 0.74 1.34 1.14 1.04 1.02 131.17 5.52 3.80
|
|
|
319 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 169 E 0.54 0.55 3.47 1.28 1.06 0.97 147.13 4.00 -3.50
|
|
|
320 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 170 G 0.54 0.37 1.11 1.21 1.07 0.95 75.07 5.52 -0.40
|
|
|
321 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 171 G 0.54 0.37 -0.50 1.08 1.06 0.98 75.07 5.52 -0.40
|
|
|
322 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 172 G 0.54 0.16 0.29 1.07 1.03 1.00 75.07 5.52 -0.40
|
|
|
323 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 173 W 0.56 0.16 -0.53 1.06 0.98 1.03 204.23 5.52 -0.90
|
|
|
324 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 174 L 0.56 0.22 -0.41 1.04 0.96 1.05 131.17 5.52 3.80
|
|
|
325 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 175 V 0.58 0.22 -0.41 1.04 0.96 1.05 117.15 5.49 4.20
|
|
|
326 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 176 A 0.58 0.28 -0.30 1.02 0.99 1.07 89.09 5.57 1.80
|
|
|
327 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 177 S 0.59 0.49 1.87 1.02 1.04 1.07 105.09 5.24 -0.80
|
|
|
328 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 178 G 0.60 0.49 2.66 1.01 1.07 1.09 75.07 5.52 -0.40
|
|
|
329 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 179 S 0.61 0.49 3.49 1.03 1.07 1.05 105.09 5.24 -0.80
|
|
|
330 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 180 T 0.62 0.36 2.59 1.02 1.03 1.01 119.12 5.19 -0.70
|
|
|
331 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 181 V 0.63 0.53 2.40 0.95 0.99 1.00 117.15 5.49 4.20
|
|
|
332 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 182 A 0.63 0.69 2.70 0.84 0.96 0.99 89.09 5.57 1.80
|
|
|
333 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 183 M 0.63 0.82 2.63 0.77 0.96 0.99 149.21 5.28 1.90
|
|
|
334 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 184 T 0.62 0.91 0.57 0.72 0.99 1.04 119.12 5.19 -0.70
|
|
|
335 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 185 E 0.63 1.57 1.96 0.79 1.00 0.99 147.13 4.00 -3.50
|
|
|
336 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 186 Q 0.62 1.57 1.06 0.78 1.00 0.96 146.15 5.52 -3.50
|
|
|
337 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 187 L 0.61 1.07 2.47 0.92 0.98 0.96 131.17 5.52 3.80
|
|
|
338 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 188 Q 0.59 0.54 0.41 0.86 0.95 0.99 146.15 5.52 -3.50
|
|
|
339 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 189 M 0.57 0.31 0.11 0.98 0.93 0.99 149.21 5.28 1.90
|
|
|
340 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 190 G 0.56 0.26 -1.89 0.91 0.93 1.01 75.07 5.52 -0.40
|
|
|
341 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 191 F 0.55 0.22 0.17 0.96 0.94 0.96 165.19 5.52 2.80
|
|
|
342 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 192 G 0.55 0.16 -1.21 0.89 0.95 1.02 75.07 5.52 -0.40
|
|
|
343 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 193 I 0.55 0.29 0.24 0.95 0.95 1.04 131.17 5.52 4.50
|
|
|
344 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 194 T 0.54 0.52 -0.84 0.89 0.95 1.08 119.12 5.19 -0.70
|
|
|
345 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 195 V 0.55 0.52 1.29 1.02 0.95 1.05 117.15 5.49 4.20
|
|
|
346 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 196 Q 0.56 1.06 1.21 0.94 0.96 1.06 146.15 5.52 -3.50
|
|
|
347 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 197 Y 0.57 1.06 3.10 1.01 0.98 1.02 181.19 5.52 -1.30
|
|
|
348 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 198 G 0.59 2.30 3.36 1.09 1.02 1.00 75.07 5.52 -0.40
|
|
|
349 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 199 T 0.59 1.78 4.81 1.23 1.05 0.95 119.12 5.19 -0.70
|
|
|
350 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 200 T 0.58 0.84 3.43 1.16 1.06 1.00 119.12 5.19 -0.70
|
|
|
351 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 201 N 0.57 0.46 3.90 1.17 1.05 1.04 132.12 5.52 -3.50
|
|
|
352 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 202 S 0.57 0.49 3.39 1.16 1.02 1.07 105.09 5.24 -0.80
|
|
|
353 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 203 V 0.56 0.68 3.46 1.17 1.00 1.07 117.15 5.49 4.20
|
|
|
354 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 204 C 0.57 0.35 1.40 1.11 0.99 1.12 121.15 5.52 2.50
|
|
|
355 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 205 P 0.56 0.45 1.51 1.00 1.00 1.13 115.13 5.96 -1.60
|
|
|
356 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 206 K 0.56 0.52 -0.73 0.88 1.00 1.14 146.19 8.75 -3.90
|
|
|
357 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 207 L 0.50 0.99 0.10 0.90 0.00 1.09 131.17 5.52 3.80
|
|
|
358 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 208 E 0.44 0.00 0.00 0.00 0.00 0.00 147.13 4.00 -3.50
|
|
|
359 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 209 F 0.38 0.00 0.00 0.00 0.00 0.00 165.19 5.52 2.80
|
|
|
360 4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD 210 A 0.32 0.00 0.00 0.00 0.00 0.00 89.09 5.57 1.80
|
|
|
361 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 1 R 0.18 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
362 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 2 S 0.22 0.00 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
363 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 3 T 0.27 1.31 0.00 0.00 0.00 0.00 119.12 5.19 -0.70
|
|
|
364 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 4 T 0.29 0.67 0.69 0.88 1.03 1.04 119.12 5.19 -0.70
|
|
|
365 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 5 L 0.32 0.42 -1.23 0.83 0.99 1.09 131.17 5.52 3.80
|
|
|
366 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 6 L 0.31 0.24 -3.47 0.71 0.95 1.13 131.17 5.52 3.80
|
|
|
367 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 7 A 0.31 0.17 -3.91 0.66 0.93 1.15 89.09 5.57 1.80
|
|
|
368 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 8 L 0.30 0.17 -5.97 0.61 0.91 1.20 131.17 5.52 3.80
|
|
|
369 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 9 L 0.29 0.15 -5.19 0.60 0.91 1.22 131.17 5.52 3.80
|
|
|
370 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 10 A 0.28 0.12 -5.19 0.60 0.91 1.22 89.09 5.57 1.80
|
|
|
371 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 11 L 0.27 0.12 -6.80 0.59 0.91 1.24 131.17 5.52 3.80
|
|
|
372 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 12 V 0.25 0.23 -5.76 0.67 0.91 1.23 117.15 5.49 4.20
|
|
|
373 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 13 L 0.25 0.19 -5.76 0.67 0.91 1.23 131.17 5.52 3.80
|
|
|
374 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 14 L 0.27 0.17 -6.59 0.64 0.90 1.28 131.17 5.52 3.80
|
|
|
375 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 15 Y 0.28 0.31 -4.34 0.76 0.91 1.24 181.19 5.52 -1.30
|
|
|
376 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 16 L 0.29 0.37 -3.00 0.91 0.93 1.17 131.17 5.52 3.80
|
|
|
377 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 17 V 0.31 0.45 -1.39 0.92 0.95 1.14 117.15 5.49 4.20
|
|
|
378 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 18 S 0.32 0.24 -1.39 0.92 0.97 1.14 105.09 5.24 -0.80
|
|
|
379 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 19 G 0.31 0.21 -1.64 0.83 0.98 1.17 75.07 5.52 -0.40
|
|
|
380 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 20 A 0.33 0.25 -1.64 0.83 0.96 1.15 89.09 5.57 1.80
|
|
|
381 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 21 L 0.35 0.37 -0.51 0.90 0.94 1.08 131.17 5.52 3.80
|
|
|
382 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 22 V 0.36 0.37 -1.14 0.79 0.93 1.09 117.15 5.49 4.20
|
|
|
383 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 23 F 0.37 0.30 -3.27 0.65 0.92 1.14 165.19 5.52 2.80
|
|
|
384 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 24 R 0.40 0.64 -2.46 0.66 0.93 1.11 174.20 9.75 -4.50
|
|
|
385 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 25 A 0.43 1.49 -0.29 0.72 0.96 1.08 89.09 5.57 1.80
|
|
|
386 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 26 L 0.44 2.66 0.54 0.86 0.99 1.03 131.17 5.52 3.80
|
|
|
387 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 27 E 0.46 1.85 2.16 0.91 1.03 1.03 147.13 4.00 -3.50
|
|
|
388 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 28 Q 0.51 3.17 2.67 0.88 1.06 1.03 146.15 5.52 -3.50
|
|
|
389 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 29 P 0.52 6.66 3.23 0.93 1.07 1.02 115.13 5.96 -1.60
|
|
|
390 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 30 H 0.53 6.66 5.40 0.98 1.06 0.99 155.16 6.74 -3.20
|
|
|
391 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 31 E 0.57 3.88 4.59 0.97 1.06 1.02 147.13 4.00 -3.50
|
|
|
392 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 32 Q 0.59 4.35 4.59 0.97 1.06 1.02 146.15 5.52 -3.50
|
|
|
393 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 33 Q 0.59 6.26 4.89 0.89 1.05 0.99 146.15 5.52 -3.50
|
|
|
394 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 34 A 0.57 6.26 5.70 0.86 1.05 0.95 89.09 5.57 1.80
|
|
|
395 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 35 Q 0.57 2.98 3.27 0.84 1.04 1.01 146.15 5.52 -3.50
|
|
|
396 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 36 R 0.57 1.70 3.23 0.92 1.03 0.99 174.20 9.75 -4.50
|
|
|
397 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 37 E 0.57 2.92 3.49 0.89 1.02 0.97 147.13 4.00 -3.50
|
|
|
398 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 38 L 0.57 1.25 2.66 0.87 1.02 1.01 131.17 5.52 3.80
|
|
|
399 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 39 G 0.58 1.25 2.40 0.86 1.02 0.99 75.07 5.52 -0.40
|
|
|
400 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 40 E 0.57 1.25 2.91 0.83 1.02 0.99 147.13 4.00 -3.50
|
|
|
401 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 41 V 0.54 3.04 2.61 0.87 1.03 1.00 117.15 5.49 4.20
|
|
|
402 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 42 R 0.53 2.66 2.61 0.87 1.03 0.98 174.20 9.75 -4.50
|
|
|
403 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 43 E 0.55 1.27 0.49 0.73 1.03 1.03 147.13 4.00 -3.50
|
|
|
404 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 44 K 0.55 3.34 -0.03 0.76 1.01 1.04 146.19 8.75 -3.90
|
|
|
405 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 45 F 0.55 1.72 0.80 0.79 0.98 0.99 165.19 5.52 2.80
|
|
|
406 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 46 L 0.54 1.35 0.50 0.79 0.96 1.02 131.17 5.52 3.80
|
|
|
407 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 47 R 0.54 1.05 -0.31 0.90 0.94 1.05 174.20 9.75 -4.50
|
|
|
408 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 48 A 0.54 0.65 -0.93 0.92 0.93 1.12 89.09 5.57 1.80
|
|
|
409 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 49 H 0.54 0.58 -0.14 0.91 0.93 1.16 155.16 6.74 -3.20
|
|
|
410 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 50 P 0.57 0.40 2.10 1.03 0.93 1.13 115.13 5.96 -1.60
|
|
|
411 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 51 C 0.57 0.66 2.93 1.10 0.94 1.13 121.15 5.52 2.50
|
|
|
412 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 52 V 0.58 0.84 3.49 1.15 0.97 1.12 117.15 5.49 4.20
|
|
|
413 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 53 S 0.58 0.94 4.30 1.12 1.01 1.09 105.09 5.24 -0.80
|
|
|
414 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 54 D 0.58 1.45 2.69 0.98 1.03 1.11 133.10 3.80 -3.50
|
|
|
415 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 55 Q 0.58 1.93 3.30 1.04 1.05 1.04 146.15 5.52 -3.50
|
|
|
416 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 56 E 0.55 1.19 2.51 1.05 1.03 1.02 147.13 4.00 -3.50
|
|
|
417 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 57 L 0.53 0.59 0.27 0.93 1.00 1.05 131.17 5.52 3.80
|
|
|
418 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 58 G 0.53 0.24 -2.30 0.79 0.97 1.09 75.07 5.52 -0.40
|
|
|
419 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 59 L 0.51 0.27 -2.34 0.79 0.95 1.08 131.17 5.52 3.80
|
|
|
420 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 60 L 0.47 0.57 -2.34 0.79 0.95 1.08 131.17 5.52 3.80
|
|
|
421 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 61 I 0.44 0.43 -1.56 0.78 0.96 1.10 131.17 5.52 4.50
|
|
|
422 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 62 K 0.44 0.53 -2.07 0.65 0.98 1.13 146.19 8.75 -3.90
|
|
|
423 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 63 E 0.43 1.07 0.67 0.78 0.98 1.07 147.13 4.00 -3.50
|
|
|
424 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 64 V 0.42 1.54 2.29 0.79 0.97 1.04 117.15 5.49 4.20
|
|
|
425 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 65 A 0.44 0.64 2.11 0.80 0.96 1.06 89.09 5.57 1.80
|
|
|
426 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 66 D 0.46 0.36 2.11 0.88 0.95 1.05 133.10 3.80 -3.50
|
|
|
427 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 67 A 0.46 0.48 1.81 1.00 0.97 1.05 89.09 5.57 1.80
|
|
|
428 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 68 L 0.47 0.47 3.16 1.15 1.00 0.98 131.17 5.52 3.80
|
|
|
429 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 69 G 0.51 0.29 3.16 1.15 1.03 0.98 75.07 5.52 -0.40
|
|
|
430 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 70 G 0.53 0.47 3.16 1.15 1.05 0.98 75.07 5.52 -0.40
|
|
|
431 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 71 G 0.55 0.89 3.16 1.27 1.06 0.98 75.07 5.52 -0.40
|
|
|
432 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 72 A 0.59 1.56 5.59 1.29 1.07 0.92 89.09 5.57 1.80
|
|
|
433 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 73 D 0.62 2.27 5.51 1.21 1.07 0.93 133.10 3.80 -3.50
|
|
|
434 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 74 P 0.63 3.07 5.63 1.19 1.07 0.95 115.13 5.96 -1.60
|
|
|
435 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 75 E 0.65 4.14 5.11 1.10 1.07 0.98 147.13 4.00 -3.50
|
|
|
436 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 76 T 0.65 3.32 5.74 1.21 1.05 0.97 119.12 5.19 -0.70
|
|
|
437 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 77 S 0.65 2.17 4.61 1.10 1.02 1.00 105.09 5.24 -0.80
|
|
|
438 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 78 H 0.65 1.32 2.89 1.02 0.99 0.98 155.16 6.74 -3.20
|
|
|
439 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 79 S 0.63 1.53 3.20 1.12 0.96 0.98 105.09 5.24 -0.80
|
|
|
440 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 80 A 0.61 0.94 1.14 1.07 0.95 1.03 89.09 5.57 1.80
|
|
|
441 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 81 W 0.58 0.68 1.03 1.09 0.94 1.01 204.23 5.52 -0.90
|
|
|
442 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 82 D 0.54 0.68 1.66 1.16 0.96 1.00 133.10 3.80 -3.50
|
|
|
443 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 83 L 0.52 0.68 1.03 1.05 0.98 1.00 131.17 5.52 3.80
|
|
|
444 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 84 G 0.49 0.56 -0.59 1.04 0.99 1.01 75.07 5.52 -0.40
|
|
|
445 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 85 S 0.46 0.29 -0.47 0.99 0.99 1.04 105.09 5.24 -0.80
|
|
|
446 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 86 A 0.42 0.31 -3.21 0.86 0.97 1.07 89.09 5.57 1.80
|
|
|
447 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 87 F 0.40 0.41 -0.97 0.98 0.95 1.03 165.19 5.52 2.80
|
|
|
448 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 88 F 0.38 0.31 -0.97 0.98 0.96 1.03 165.19 5.52 2.80
|
|
|
449 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 89 F 0.35 0.44 -1.16 0.92 0.98 1.02 165.19 5.52 2.80
|
|
|
450 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 90 S 0.34 0.35 -2.60 0.89 1.01 1.03 105.09 5.24 -0.80
|
|
|
451 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 91 G 0.34 0.29 -2.43 0.87 1.02 1.04 75.07 5.52 -0.40
|
|
|
452 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 92 T 0.35 0.48 -0.37 0.92 1.01 1.01 119.12 5.19 -0.70
|
|
|
453 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 93 I 0.37 0.51 1.69 0.97 0.99 0.99 131.17 5.52 4.50
|
|
|
454 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 94 I 0.39 0.36 -0.39 0.84 0.98 1.01 131.17 5.52 4.50
|
|
|
455 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 95 T 0.44 0.25 -0.39 0.84 0.99 1.01 119.12 5.19 -0.70
|
|
|
456 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 96 T 0.48 0.56 -1.40 0.86 0.99 1.04 119.12 5.19 -0.70
|
|
|
457 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 97 I 0.50 0.79 0.56 1.02 0.99 1.00 131.17 5.52 4.50
|
|
|
458 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 98 G 0.53 0.88 2.70 1.17 0.99 0.95 75.07 5.52 -0.40
|
|
|
459 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 99 Y 0.56 0.45 1.43 1.11 0.98 1.02 181.19 5.52 -1.30
|
|
|
460 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 100 G 0.57 0.65 0.99 1.06 0.98 1.04 75.07 5.52 -0.40
|
|
|
461 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 101 N 0.60 0.54 0.81 1.08 0.97 1.05 132.12 5.52 -3.50
|
|
|
462 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 102 V 0.58 0.68 0.60 0.99 0.96 1.05 117.15 5.49 4.20
|
|
|
463 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 103 A 0.58 0.99 1.61 0.97 0.96 1.02 89.09 5.57 1.80
|
|
|
464 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 104 L 0.57 1.03 2.23 0.95 0.98 1.02 131.17 5.52 3.80
|
|
|
465 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 105 R 0.55 1.40 1.53 0.83 1.01 1.06 174.20 9.75 -4.50
|
|
|
466 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 106 T 0.54 1.37 2.87 0.98 1.04 0.99 119.12 5.19 -0.70
|
|
|
467 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 107 D 0.52 3.25 3.17 1.02 1.05 0.96 133.10 3.80 -3.50
|
|
|
468 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 108 A 0.49 1.37 3.17 1.02 1.05 0.96 89.09 5.57 1.80
|
|
|
469 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 109 G 0.47 0.82 1.26 0.97 1.03 0.99 75.07 5.52 -0.40
|
|
|
470 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 110 R 0.42 0.26 0.71 1.00 1.00 1.06 174.20 9.75 -4.50
|
|
|
471 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 111 L 0.39 0.18 -1.86 0.86 0.97 1.10 131.17 5.52 3.80
|
|
|
472 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 112 F 0.36 0.16 -3.47 0.85 0.94 1.11 165.19 5.52 2.80
|
|
|
473 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 113 C 0.32 0.13 -4.56 0.79 0.92 1.15 121.15 5.52 2.50
|
|
|
474 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 114 I 0.30 0.16 -4.86 0.75 0.90 1.17 131.17 5.52 4.50
|
|
|
475 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 115 F 0.28 0.15 -4.86 0.75 0.89 1.17 165.19 5.52 2.80
|
|
|
476 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 116 Y 0.26 0.21 -4.07 0.74 0.89 1.22 181.19 5.52 -1.30
|
|
|
477 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 117 A 0.26 0.29 -3.46 0.79 0.89 1.14 89.09 5.57 1.80
|
|
|
478 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 118 L 0.27 0.24 -3.46 0.79 0.91 1.14 131.17 5.52 3.80
|
|
|
479 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 119 V 0.28 0.23 -1.84 0.92 0.92 1.14 117.15 5.49 4.20
|
|
|
480 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 120 G 0.29 0.19 -2.89 0.84 0.94 1.15 75.07 5.52 -0.40
|
|
|
481 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 121 I 0.29 0.20 -4.50 0.83 0.95 1.15 131.17 5.52 4.50
|
|
|
482 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 122 P 0.31 0.27 -2.37 0.97 0.95 1.10 115.13 5.96 -1.60
|
|
|
483 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 123 L 0.32 0.19 -2.99 0.97 0.94 1.07 131.17 5.52 3.80
|
|
|
484 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 124 F 0.32 0.22 -5.11 0.83 0.93 1.12 165.19 5.52 2.80
|
|
|
485 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 125 G 0.33 0.12 -5.29 0.85 0.92 1.13 75.07 5.52 -0.40
|
|
|
486 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 126 I 0.34 0.15 -5.29 0.72 0.92 1.13 131.17 5.52 4.50
|
|
|
487 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 127 L 0.35 0.17 -3.16 0.86 0.92 1.08 131.17 5.52 3.80
|
|
|
488 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 128 L 0.37 0.12 -2.37 0.85 0.93 1.12 131.17 5.52 3.80
|
|
|
489 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 129 A 0.39 0.18 -2.37 0.85 0.94 1.12 89.09 5.57 1.80
|
|
|
490 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 130 G 0.43 0.36 0.20 0.99 0.96 1.08 75.07 5.52 -0.40
|
|
|
491 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 131 V 0.44 0.85 2.11 1.04 0.98 1.03 117.15 5.49 4.20
|
|
|
492 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 132 G 0.46 0.69 2.11 1.04 1.00 1.03 75.07 5.52 -0.40
|
|
|
493 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 133 D 0.47 0.69 2.63 1.17 1.01 1.00 133.10 3.80 -3.50
|
|
|
494 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 134 R 0.48 1.25 2.74 1.15 1.03 1.02 174.20 9.75 -4.50
|
|
|
495 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 135 L 0.49 1.69 4.20 1.28 1.04 0.97 131.17 5.52 3.80
|
|
|
496 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 136 G 0.50 0.83 2.07 1.14 1.05 1.02 75.07 5.52 -0.40
|
|
|
497 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 137 S 0.51 0.83 1.24 1.07 1.05 1.02 105.09 5.24 -0.80
|
|
|
498 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 138 S 0.50 1.37 0.94 1.07 1.03 1.05 105.09 5.24 -0.80
|
|
|
499 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 139 L 0.50 1.37 3.07 1.21 1.00 1.00 131.17 5.52 3.80
|
|
|
500 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 140 R 0.49 0.72 1.11 1.05 0.97 1.04 174.20 9.75 -4.50
|
|
|
501 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 141 H 0.50 0.53 1.00 1.07 0.96 1.02 155.16 6.74 -3.20
|
|
|
502 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 142 G 0.51 0.88 0.37 1.00 0.95 1.03 75.07 5.52 -0.40
|
|
|
503 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 143 I 0.52 0.31 0.54 0.99 0.95 1.02 131.17 5.52 4.50
|
|
|
504 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 144 G 0.53 0.40 1.06 0.96 0.94 1.02 75.07 5.52 -0.40
|
|
|
505 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 145 H 0.53 0.41 1.06 0.92 0.94 1.01 155.16 6.74 -3.20
|
|
|
506 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 146 I 0.53 0.41 -0.90 0.76 0.93 1.05 131.17 5.52 4.50
|
|
|
507 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 147 E 0.54 0.36 -1.07 0.78 0.92 1.04 147.13 4.00 -3.50
|
|
|
508 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 148 A 0.55 0.22 -3.20 0.64 0.92 1.10 89.09 5.57 1.80
|
|
|
509 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 149 I 0.57 0.62 -2.69 0.65 0.93 1.07 131.17 5.52 4.50
|
|
|
510 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 150 F 0.59 0.37 -2.97 0.72 0.94 1.03 165.19 5.52 2.80
|
|
|
511 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 151 L 0.60 0.50 -3.79 0.75 0.95 1.07 131.17 5.52 3.80
|
|
|
512 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 152 K 0.61 0.53 -4.61 0.73 0.95 1.11 146.19 8.75 -3.90
|
|
|
513 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 153 W 0.62 0.95 -3.17 0.88 0.96 1.10 204.23 5.52 -0.90
|
|
|
514 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 154 H 0.63 1.79 -1.56 1.01 0.96 1.10 155.16 6.74 -3.20
|
|
|
515 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 155 V 0.64 1.55 0.87 1.03 0.98 1.04 117.15 5.49 4.20
|
|
|
516 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 156 P 0.65 1.21 -1.26 0.97 1.00 1.09 115.13 5.96 -1.60
|
|
|
517 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 157 P 0.66 0.66 -0.36 0.90 1.01 1.16 115.13 5.96 -1.60
|
|
|
518 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 158 E 0.65 1.75 -0.06 0.90 1.00 1.12 147.13 4.00 -3.50
|
|
|
519 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 159 L 0.64 0.84 -0.06 0.90 0.98 1.12 131.17 5.52 3.80
|
|
|
520 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 160 V 0.64 0.45 -1.67 0.77 0.95 1.15 117.15 5.49 4.20
|
|
|
521 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 161 R 0.63 0.35 -1.04 0.76 0.94 1.14 174.20 9.75 -4.50
|
|
|
522 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 162 V 0.63 0.42 -1.86 0.75 0.93 1.17 117.15 5.49 4.20
|
|
|
523 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 163 L 0.62 0.57 -1.14 0.75 0.93 1.11 131.17 5.52 3.80
|
|
|
524 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 164 S 0.61 0.24 -1.93 0.76 0.92 1.09 105.09 5.24 -0.80
|
|
|
525 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 165 A 0.60 0.28 -3.84 0.71 0.91 1.13 89.09 5.57 1.80
|
|
|
526 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 166 M 0.57 0.28 -4.63 0.72 0.90 1.11 149.21 5.28 1.90
|
|
|
527 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 167 L 0.56 0.17 -4.63 0.72 0.90 1.11 131.17 5.52 3.80
|
|
|
528 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 168 F 0.53 0.12 -6.70 0.59 0.90 1.13 165.19 5.52 2.80
|
|
|
529 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 169 L 0.49 0.12 -6.19 0.71 0.91 1.10 131.17 5.52 3.80
|
|
|
530 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 170 L 0.47 0.08 -5.39 0.80 0.91 1.18 131.17 5.52 3.80
|
|
|
531 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 171 I 0.43 0.07 -5.39 0.80 0.91 1.18 131.17 5.52 4.50
|
|
|
532 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 172 G 0.40 0.07 -5.39 0.80 0.91 1.21 75.07 5.52 -0.40
|
|
|
533 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 173 C 0.36 0.08 -5.39 0.80 0.91 1.18 121.15 5.52 2.50
|
|
|
534 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 174 L 0.31 0.08 -4.60 0.79 0.91 1.20 131.17 5.52 3.80
|
|
|
535 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 175 L 0.28 0.07 -4.77 0.80 0.92 1.22 131.17 5.52 3.80
|
|
|
536 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 176 F 0.26 0.18 -4.84 0.72 0.93 1.22 165.19 5.52 2.80
|
|
|
537 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 177 V 0.26 0.34 -4.74 0.76 0.95 1.17 117.15 5.49 4.20
|
|
|
538 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 178 L 0.26 0.60 -2.69 0.82 0.98 1.12 131.17 5.52 3.80
|
|
|
539 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 179 T 0.26 0.60 -2.69 0.82 1.00 1.10 119.12 5.19 -0.70
|
|
|
540 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 180 P 0.26 0.60 -1.90 0.80 1.01 1.14 115.13 5.96 -1.60
|
|
|
541 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 181 T 0.27 0.63 -2.69 0.82 0.99 1.10 119.12 5.19 -0.70
|
|
|
542 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 182 F 0.30 0.23 -1.17 0.90 0.97 1.12 165.19 5.52 2.80
|
|
|
543 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 183 V 0.34 0.24 -2.19 0.93 0.94 1.16 117.15 5.49 4.20
|
|
|
544 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 184 F 0.38 0.16 -3.09 0.80 0.91 1.12 165.19 5.52 2.80
|
|
|
545 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 185 C 0.42 0.33 -2.71 0.77 0.90 1.12 121.15 5.52 2.50
|
|
|
546 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 186 Y 0.45 0.73 0.03 0.89 0.91 1.08 181.19 5.52 -1.30
|
|
|
547 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 187 M 0.48 0.89 -0.87 0.96 0.93 1.01 149.21 5.28 1.90
|
|
|
548 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 188 E 0.51 2.22 1.37 1.07 0.97 1.00 147.13 4.00 -3.50
|
|
|
549 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 189 D 0.53 2.84 1.99 1.05 1.00 0.93 133.10 3.80 -3.50
|
|
|
550 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 190 W 0.54 2.36 0.94 0.97 1.01 0.95 204.23 5.52 -0.90
|
|
|
551 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 191 S 0.53 2.36 2.66 0.99 1.02 0.95 105.09 5.24 -0.80
|
|
|
552 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 192 K 0.52 1.43 1.84 0.98 1.01 0.98 146.19 8.75 -3.90
|
|
|
553 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 193 L 0.47 0.95 -0.73 0.84 0.98 1.02 131.17 5.52 3.80
|
|
|
554 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 194 E 0.43 1.12 0.43 0.86 0.95 1.06 147.13 4.00 -3.50
|
|
|
555 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 195 A 0.39 0.48 -1.81 0.74 0.93 1.07 89.09 5.57 1.80
|
|
|
556 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 196 I 0.35 0.43 -3.16 0.67 0.90 1.14 131.17 5.52 4.50
|
|
|
557 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 197 Y 0.32 0.19 -2.37 0.66 0.89 1.15 181.19 5.52 -1.30
|
|
|
558 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 198 F 0.29 0.27 -2.74 0.69 0.90 1.16 165.19 5.52 2.80
|
|
|
559 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 199 V 0.26 0.31 -4.36 0.68 0.91 1.19 117.15 5.49 4.20
|
|
|
560 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 200 V 0.25 0.29 -2.47 0.75 0.93 1.16 117.15 5.49 4.20
|
|
|
561 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 201 T 0.24 0.48 -1.46 0.72 0.96 1.12 119.12 5.19 -0.70
|
|
|
562 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 202 L 0.26 0.48 -0.67 0.71 0.98 1.16 131.17 5.52 3.80
|
|
|
563 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 203 T 0.28 0.64 0.67 0.86 1.00 1.09 119.12 5.19 -0.70
|
|
|
564 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 204 T 0.32 0.38 -0.11 0.88 1.00 1.05 119.12 5.19 -0.70
|
|
|
565 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 205 V 0.35 0.46 -0.04 0.96 0.99 1.04 117.15 5.49 4.20
|
|
|
566 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 206 G 0.37 0.53 2.70 1.09 0.98 0.99 75.07 5.52 -0.40
|
|
|
567 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 207 F 0.40 0.58 1.69 1.11 0.98 1.02 165.19 5.52 2.80
|
|
|
568 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 208 G 0.43 0.58 0.41 1.05 0.99 1.09 75.07 5.52 -0.40
|
|
|
569 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 209 D 0.46 0.59 1.24 1.07 0.99 1.04 133.10 3.80 -3.50
|
|
|
570 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 210 Y 0.49 0.68 1.24 1.07 0.97 1.04 181.19 5.52 -1.30
|
|
|
571 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 211 V 0.51 0.69 2.86 1.08 0.96 1.04 117.15 5.49 4.20
|
|
|
572 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 212 A 0.54 0.69 3.47 1.06 0.96 1.04 89.09 5.57 1.80
|
|
|
573 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 213 G 0.56 0.68 2.34 1.07 0.98 1.07 75.07 5.52 -0.40
|
|
|
574 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 214 A 0.58 1.80 3.21 1.04 1.01 1.03 89.09 5.57 1.80
|
|
|
575 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 215 D 0.59 3.08 4.60 1.11 1.04 0.97 133.10 3.80 -3.50
|
|
|
576 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 216 P 0.60 5.20 5.73 1.23 1.06 0.95 115.13 5.96 -1.60
|
|
|
577 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 217 R 0.62 6.90 5.84 1.21 1.08 0.97 174.20 9.75 -4.50
|
|
|
578 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 218 Q 0.64 6.39 5.84 1.33 1.09 0.97 146.15 5.52 -3.50
|
|
|
579 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 219 D 0.64 4.17 4.71 1.22 1.09 0.99 133.10 3.80 -3.50
|
|
|
580 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 220 S 0.63 3.34 4.14 1.16 1.08 1.01 105.09 5.24 -0.80
|
|
|
581 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 221 P 0.61 3.34 4.40 1.17 1.05 1.03 115.13 5.96 -1.60
|
|
|
582 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 222 A 0.58 3.09 3.84 1.24 1.02 1.04 89.09 5.57 1.80
|
|
|
583 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 223 Y 0.55 1.90 1.10 1.12 1.01 1.09 181.19 5.52 -1.30
|
|
|
584 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 224 Q 0.52 0.91 -0.36 0.99 1.00 1.14 146.15 5.52 -3.50
|
|
|
585 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 225 P 0.49 0.95 -2.09 0.91 0.98 1.12 115.13 5.96 -1.60
|
|
|
586 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 226 L 0.45 0.53 -3.70 0.90 0.96 1.12 131.17 5.52 3.80
|
|
|
587 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 227 V 0.40 0.32 -4.86 0.87 0.92 1.08 117.15 5.49 4.20
|
|
|
588 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 228 W 0.37 0.14 -6.86 0.80 0.89 1.10 204.23 5.52 -0.90
|
|
|
589 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 229 F 0.33 0.14 -8.47 0.67 0.87 1.13 165.19 5.52 2.80
|
|
|
590 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 230 W 0.30 0.16 -8.47 0.67 0.87 1.13 204.23 5.52 -0.90
|
|
|
591 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 231 I 0.28 0.15 -7.13 0.82 0.88 1.06 131.17 5.52 4.50
|
|
|
592 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 232 L 0.28 0.14 -7.01 0.77 0.91 1.11 131.17 5.52 3.80
|
|
|
593 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 233 L 0.29 0.14 -5.40 0.77 0.92 1.10 131.17 5.52 3.80
|
|
|
594 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 234 G 0.28 0.31 -4.24 0.80 0.92 1.14 75.07 5.52 -0.40
|
|
|
595 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 235 L 0.27 0.32 -4.41 0.82 0.92 1.13 131.17 5.52 3.80
|
|
|
596 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 236 A 0.29 0.40 -2.80 0.83 0.91 1.11 89.09 5.57 1.80
|
|
|
597 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 237 Y 0.29 0.54 -0.56 0.95 0.90 1.07 181.19 5.52 -1.30
|
|
|
598 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 238 F 0.32 0.48 -1.90 0.80 0.91 1.15 165.19 5.52 2.80
|
|
|
599 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 239 A 0.34 0.40 -1.90 0.80 0.92 1.15 89.09 5.57 1.80
|
|
|
600 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 240 S 0.37 0.36 -1.46 0.84 0.93 1.12 105.09 5.24 -0.80
|
|
|
601 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 241 V 0.36 0.61 -0.44 0.81 0.96 1.09 117.15 5.49 4.20
|
|
|
602 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 242 L 0.35 0.42 -0.27 0.80 0.98 1.10 131.17 5.52 3.80
|
|
|
603 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 243 T 0.37 0.31 0.24 0.92 1.00 1.07 119.12 5.19 -0.70
|
|
|
604 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 244 T 0.41 0.67 0.31 0.94 1.02 1.04 119.12 5.19 -0.70
|
|
|
605 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 245 I 0.40 0.86 -0.59 1.01 1.02 0.97 131.17 5.52 4.50
|
|
|
606 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 246 G 0.43 0.49 -0.59 1.01 1.01 0.97 75.07 5.52 -0.40
|
|
|
607 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 247 N 0.44 0.67 -0.73 1.01 0.99 0.96 132.12 5.52 -3.50
|
|
|
608 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 248 W 0.43 0.71 -2.00 0.94 0.96 1.03 204.23 5.52 -0.90
|
|
|
609 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 249 L 0.37 0.53 -1.39 0.95 0.00 1.06 131.17 5.52 3.80
|
|
|
610 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 250 R 0.34 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
611 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 251 V 0.30 0.00 0.00 0.00 0.00 0.00 117.15 5.49 4.20
|
|
|
612 4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation 252 V 0.24 0.00 0.00 0.00 0.00 0.00 117.15 5.49 4.20
|
|
|
613 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 1 R 0.19 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
614 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 2 S 0.23 0.00 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
615 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 3 T 0.27 1.27 0.00 0.00 0.00 0.00 119.12 5.19 -0.70
|
|
|
616 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 4 T 0.30 0.66 0.69 0.88 1.03 1.04 119.12 5.19 -0.70
|
|
|
617 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 5 L 0.32 0.40 -1.23 0.83 0.99 1.09 131.17 5.52 3.80
|
|
|
618 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 6 L 0.32 0.23 -3.47 0.71 0.95 1.13 131.17 5.52 3.80
|
|
|
619 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 7 A 0.31 0.16 -3.91 0.66 0.93 1.15 89.09 5.57 1.80
|
|
|
620 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 8 L 0.30 0.16 -5.97 0.61 0.91 1.20 131.17 5.52 3.80
|
|
|
621 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 9 L 0.29 0.15 -5.19 0.60 0.91 1.22 131.17 5.52 3.80
|
|
|
622 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 10 A 0.29 0.12 -5.19 0.60 0.91 1.22 89.09 5.57 1.80
|
|
|
623 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 11 L 0.28 0.12 -6.80 0.59 0.91 1.24 131.17 5.52 3.80
|
|
|
624 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 12 V 0.26 0.23 -5.76 0.67 0.91 1.23 117.15 5.49 4.20
|
|
|
625 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 13 L 0.25 0.18 -5.76 0.67 0.91 1.23 131.17 5.52 3.80
|
|
|
626 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 14 L 0.27 0.17 -6.59 0.64 0.90 1.28 131.17 5.52 3.80
|
|
|
627 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 15 Y 0.28 0.30 -4.34 0.76 0.91 1.24 181.19 5.52 -1.30
|
|
|
628 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 16 L 0.30 0.36 -3.00 0.91 0.93 1.17 131.17 5.52 3.80
|
|
|
629 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 17 V 0.32 0.44 -1.39 0.92 0.95 1.14 117.15 5.49 4.20
|
|
|
630 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 18 S 0.33 0.23 -1.39 0.92 0.97 1.14 105.09 5.24 -0.80
|
|
|
631 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 19 G 0.31 0.21 -1.64 0.83 0.98 1.17 75.07 5.52 -0.40
|
|
|
632 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 20 A 0.33 0.24 -1.64 0.83 0.96 1.15 89.09 5.57 1.80
|
|
|
633 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 21 L 0.36 0.36 -0.51 0.90 0.94 1.08 131.17 5.52 3.80
|
|
|
634 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 22 V 0.37 0.36 -1.14 0.79 0.93 1.09 117.15 5.49 4.20
|
|
|
635 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 23 F 0.38 0.30 -3.27 0.65 0.92 1.14 165.19 5.52 2.80
|
|
|
636 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 24 R 0.41 0.62 -2.46 0.66 0.93 1.11 174.20 9.75 -4.50
|
|
|
637 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 25 A 0.44 1.45 -0.29 0.72 0.96 1.08 89.09 5.57 1.80
|
|
|
638 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 26 L 0.46 2.59 0.54 0.86 0.99 1.03 131.17 5.52 3.80
|
|
|
639 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 27 E 0.48 1.80 2.16 0.91 1.03 1.03 147.13 4.00 -3.50
|
|
|
640 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 28 Q 0.53 3.09 2.67 0.88 1.06 1.03 146.15 5.52 -3.50
|
|
|
641 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 29 P 0.54 6.48 3.23 0.93 1.07 1.02 115.13 5.96 -1.60
|
|
|
642 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 30 H 0.55 6.48 5.40 0.98 1.06 0.99 155.16 6.74 -3.20
|
|
|
643 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 31 E 0.59 3.78 4.59 0.97 1.06 1.02 147.13 4.00 -3.50
|
|
|
644 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 32 Q 0.61 4.23 4.59 0.97 1.06 1.02 146.15 5.52 -3.50
|
|
|
645 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 33 Q 0.61 6.09 4.89 0.89 1.05 0.99 146.15 5.52 -3.50
|
|
|
646 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 34 A 0.59 6.09 5.70 0.86 1.05 0.95 89.09 5.57 1.80
|
|
|
647 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 35 Q 0.58 2.90 3.27 0.84 1.04 1.01 146.15 5.52 -3.50
|
|
|
648 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 36 R 0.58 1.66 3.23 0.92 1.03 0.99 174.20 9.75 -4.50
|
|
|
649 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 37 E 0.58 2.84 3.49 0.89 1.02 0.97 147.13 4.00 -3.50
|
|
|
650 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 38 L 0.57 1.22 2.66 0.87 1.02 1.01 131.17 5.52 3.80
|
|
|
651 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 39 G 0.58 1.22 2.40 0.86 1.02 0.99 75.07 5.52 -0.40
|
|
|
652 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 40 E 0.58 1.22 2.91 0.83 1.02 0.99 147.13 4.00 -3.50
|
|
|
653 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 41 V 0.55 2.95 2.61 0.87 1.03 1.00 117.15 5.49 4.20
|
|
|
654 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 42 R 0.53 2.58 2.61 0.87 1.03 0.98 174.20 9.75 -4.50
|
|
|
655 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 43 E 0.55 1.23 0.49 0.73 1.03 1.03 147.13 4.00 -3.50
|
|
|
656 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 44 K 0.55 3.25 -0.03 0.76 1.01 1.04 146.19 8.75 -3.90
|
|
|
657 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 45 F 0.55 1.68 0.80 0.79 0.98 0.99 165.19 5.52 2.80
|
|
|
658 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 46 L 0.54 1.32 0.50 0.79 0.96 1.02 131.17 5.52 3.80
|
|
|
659 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 47 R 0.54 1.02 -0.31 0.90 0.94 1.05 174.20 9.75 -4.50
|
|
|
660 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 48 A 0.53 0.63 -0.93 0.92 0.93 1.12 89.09 5.57 1.80
|
|
|
661 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 49 H 0.53 0.57 -0.14 0.91 0.93 1.16 155.16 6.74 -3.20
|
|
|
662 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 50 P 0.56 0.39 2.10 1.03 0.93 1.13 115.13 5.96 -1.60
|
|
|
663 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 51 C 0.57 0.64 2.93 1.10 0.94 1.13 121.15 5.52 2.50
|
|
|
664 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 52 V 0.58 0.82 3.49 1.15 0.97 1.12 117.15 5.49 4.20
|
|
|
665 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 53 S 0.57 0.91 4.30 1.12 1.01 1.09 105.09 5.24 -0.80
|
|
|
666 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 54 D 0.58 1.41 2.69 0.98 1.03 1.11 133.10 3.80 -3.50
|
|
|
667 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 55 Q 0.58 1.88 3.30 1.04 1.05 1.04 146.15 5.52 -3.50
|
|
|
668 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 56 E 0.55 1.15 2.51 1.05 1.03 1.02 147.13 4.00 -3.50
|
|
|
669 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 57 L 0.52 0.57 0.27 0.93 1.00 1.05 131.17 5.52 3.80
|
|
|
670 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 58 G 0.51 0.23 -2.30 0.79 0.97 1.09 75.07 5.52 -0.40
|
|
|
671 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 59 L 0.49 0.27 -2.34 0.79 0.95 1.08 131.17 5.52 3.80
|
|
|
672 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 60 L 0.46 0.56 -2.34 0.79 0.95 1.08 131.17 5.52 3.80
|
|
|
673 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 61 I 0.43 0.42 -1.56 0.78 0.96 1.10 131.17 5.52 4.50
|
|
|
674 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 62 K 0.42 0.51 -2.07 0.65 0.98 1.13 146.19 8.75 -3.90
|
|
|
675 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 63 E 0.41 1.04 0.67 0.78 0.98 1.07 147.13 4.00 -3.50
|
|
|
676 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 64 V 0.39 1.50 2.29 0.79 0.97 1.04 117.15 5.49 4.20
|
|
|
677 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 65 A 0.42 0.62 2.11 0.80 0.96 1.06 89.09 5.57 1.80
|
|
|
678 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 66 D 0.44 0.35 2.11 0.88 0.95 1.05 133.10 3.80 -3.50
|
|
|
679 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 67 A 0.44 0.47 1.81 1.00 0.97 1.05 89.09 5.57 1.80
|
|
|
680 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 68 L 0.44 0.46 3.16 1.15 1.00 0.98 131.17 5.52 3.80
|
|
|
681 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 69 G 0.48 0.28 3.16 1.15 1.03 0.98 75.07 5.52 -0.40
|
|
|
682 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 70 G 0.50 0.46 3.16 1.15 1.05 0.98 75.07 5.52 -0.40
|
|
|
683 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 71 G 0.52 0.87 3.16 1.27 1.06 0.98 75.07 5.52 -0.40
|
|
|
684 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 72 A 0.55 1.51 5.59 1.29 1.07 0.92 89.09 5.57 1.80
|
|
|
685 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 73 D 0.59 2.21 5.51 1.21 1.07 0.93 133.10 3.80 -3.50
|
|
|
686 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 74 P 0.62 3.87 5.56 1.13 1.08 0.95 115.13 5.96 -1.60
|
|
|
687 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 75 E 0.63 5.13 5.67 1.11 1.09 0.97 147.13 4.00 -3.50
|
|
|
688 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 76 T 0.65 4.11 6.30 1.22 1.10 0.96 119.12 5.19 -0.70
|
|
|
689 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 77 Q 0.68 3.62 5.17 1.14 1.11 1.00 146.15 5.52 -3.50
|
|
|
690 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 78 S 0.68 2.80 5.80 1.13 1.09 0.99 105.09 5.24 -0.80
|
|
|
691 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 79 S 0.68 1.96 4.99 1.12 1.05 1.02 105.09 5.24 -0.80
|
|
|
692 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 80 H 0.67 1.19 2.81 1.12 1.01 1.02 155.16 6.74 -3.20
|
|
|
693 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 81 S 0.65 1.48 3.39 1.19 0.97 0.99 105.09 5.24 -0.80
|
|
|
694 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 82 A 0.63 0.91 1.14 1.07 0.95 1.03 89.09 5.57 1.80
|
|
|
695 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 83 W 0.61 0.66 1.03 1.09 0.94 1.01 204.23 5.52 -0.90
|
|
|
696 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 84 D 0.59 0.66 1.66 1.16 0.96 1.00 133.10 3.80 -3.50
|
|
|
697 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 85 L 0.55 0.66 1.03 1.05 0.98 1.00 131.17 5.52 3.80
|
|
|
698 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 86 G 0.54 0.55 -0.59 1.04 0.99 1.01 75.07 5.52 -0.40
|
|
|
699 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 87 S 0.52 0.28 -0.47 0.99 0.99 1.04 105.09 5.24 -0.80
|
|
|
700 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 88 A 0.48 0.30 -3.21 0.86 0.97 1.07 89.09 5.57 1.80
|
|
|
701 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 89 F 0.46 0.40 -0.97 0.98 0.95 1.03 165.19 5.52 2.80
|
|
|
702 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 90 F 0.43 0.30 -0.97 0.98 0.96 1.03 165.19 5.52 2.80
|
|
|
703 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 91 F 0.40 0.43 -1.16 0.92 0.98 1.02 165.19 5.52 2.80
|
|
|
704 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 92 S 0.37 0.34 -2.60 0.89 1.01 1.03 105.09 5.24 -0.80
|
|
|
705 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 93 G 0.35 0.28 -2.43 0.87 1.02 1.04 75.07 5.52 -0.40
|
|
|
706 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 94 T 0.36 0.46 -0.37 0.92 1.01 1.01 119.12 5.19 -0.70
|
|
|
707 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 95 I 0.35 0.50 1.69 0.97 0.99 0.99 131.17 5.52 4.50
|
|
|
708 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 96 I 0.36 0.35 -0.39 0.84 0.98 1.01 131.17 5.52 4.50
|
|
|
709 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 97 T 0.38 0.24 -0.39 0.84 0.99 1.01 119.12 5.19 -0.70
|
|
|
710 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 98 T 0.41 0.54 -1.40 0.86 0.99 1.04 119.12 5.19 -0.70
|
|
|
711 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 99 I 0.44 0.77 0.56 1.02 0.99 1.00 131.17 5.52 4.50
|
|
|
712 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 100 G 0.48 0.85 2.70 1.17 0.99 0.95 75.07 5.52 -0.40
|
|
|
713 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 101 Y 0.52 0.44 1.43 1.11 0.98 1.02 181.19 5.52 -1.30
|
|
|
714 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 102 G 0.57 0.63 0.99 1.06 0.98 1.04 75.07 5.52 -0.40
|
|
|
715 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 103 N 0.60 0.53 0.81 1.08 0.97 1.05 132.12 5.52 -3.50
|
|
|
716 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 104 V 0.60 0.66 0.60 0.99 0.96 1.05 117.15 5.49 4.20
|
|
|
717 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 105 A 0.62 0.96 1.61 0.97 0.96 1.02 89.09 5.57 1.80
|
|
|
718 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 106 L 0.62 1.00 2.23 0.95 0.98 1.02 131.17 5.52 3.80
|
|
|
719 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 107 R 0.62 1.36 1.53 0.83 1.01 1.06 174.20 9.75 -4.50
|
|
|
720 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 108 T 0.62 1.33 2.87 0.98 1.04 0.99 119.12 5.19 -0.70
|
|
|
721 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 109 D 0.60 3.16 3.17 1.02 1.05 0.96 133.10 3.80 -3.50
|
|
|
722 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 110 A 0.58 1.33 3.17 1.02 1.05 0.96 89.09 5.57 1.80
|
|
|
723 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 111 G 0.54 0.80 1.26 0.97 1.03 0.99 75.07 5.52 -0.40
|
|
|
724 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 112 R 0.50 0.26 0.71 1.00 1.00 1.06 174.20 9.75 -4.50
|
|
|
725 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 113 L 0.46 0.18 -1.86 0.86 0.97 1.10 131.17 5.52 3.80
|
|
|
726 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 114 F 0.43 0.16 -3.47 0.85 0.94 1.11 165.19 5.52 2.80
|
|
|
727 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 115 C 0.39 0.12 -4.56 0.79 0.92 1.15 121.15 5.52 2.50
|
|
|
728 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 116 I 0.35 0.15 -4.86 0.75 0.90 1.17 131.17 5.52 4.50
|
|
|
729 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 117 F 0.32 0.15 -4.86 0.75 0.89 1.17 165.19 5.52 2.80
|
|
|
730 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 118 Y 0.29 0.20 -4.07 0.74 0.89 1.22 181.19 5.52 -1.30
|
|
|
731 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 119 A 0.28 0.28 -3.46 0.79 0.89 1.14 89.09 5.57 1.80
|
|
|
732 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 120 L 0.28 0.23 -3.46 0.79 0.91 1.14 131.17 5.52 3.80
|
|
|
733 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 121 V 0.29 0.23 -1.84 0.92 0.92 1.14 117.15 5.49 4.20
|
|
|
734 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 122 G 0.30 0.19 -2.89 0.84 0.94 1.15 75.07 5.52 -0.40
|
|
|
735 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 123 I 0.30 0.19 -4.50 0.83 0.95 1.15 131.17 5.52 4.50
|
|
|
736 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 124 P 0.31 0.26 -2.37 0.97 0.95 1.10 115.13 5.96 -1.60
|
|
|
737 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 125 L 0.32 0.18 -2.99 0.97 0.94 1.07 131.17 5.52 3.80
|
|
|
738 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 126 F 0.33 0.22 -5.11 0.83 0.93 1.12 165.19 5.52 2.80
|
|
|
739 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 127 G 0.34 0.12 -5.29 0.85 0.92 1.13 75.07 5.52 -0.40
|
|
|
740 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 128 I 0.35 0.14 -5.29 0.72 0.92 1.13 131.17 5.52 4.50
|
|
|
741 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 129 L 0.36 0.16 -3.16 0.86 0.92 1.08 131.17 5.52 3.80
|
|
|
742 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 130 L 0.38 0.12 -2.37 0.85 0.93 1.12 131.17 5.52 3.80
|
|
|
743 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 131 A 0.40 0.17 -2.37 0.85 0.94 1.12 89.09 5.57 1.80
|
|
|
744 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 132 G 0.44 0.35 0.20 0.99 0.96 1.08 75.07 5.52 -0.40
|
|
|
745 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 133 V 0.46 0.82 2.11 1.04 0.98 1.03 117.15 5.49 4.20
|
|
|
746 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 134 G 0.48 0.67 2.11 1.04 1.00 1.03 75.07 5.52 -0.40
|
|
|
747 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 135 D 0.50 0.67 2.63 1.17 1.01 1.00 133.10 3.80 -3.50
|
|
|
748 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 136 R 0.52 1.21 2.74 1.15 1.03 1.02 174.20 9.75 -4.50
|
|
|
749 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 137 L 0.54 1.64 4.20 1.28 1.04 0.97 131.17 5.52 3.80
|
|
|
750 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 138 G 0.55 0.81 2.07 1.14 1.05 1.02 75.07 5.52 -0.40
|
|
|
751 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 139 S 0.56 0.81 1.24 1.07 1.05 1.02 105.09 5.24 -0.80
|
|
|
752 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 140 S 0.56 1.34 0.94 1.07 1.03 1.05 105.09 5.24 -0.80
|
|
|
753 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 141 L 0.55 1.34 3.07 1.21 1.00 1.00 131.17 5.52 3.80
|
|
|
754 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 142 R 0.54 0.70 1.11 1.05 0.97 1.04 174.20 9.75 -4.50
|
|
|
755 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 143 H 0.55 0.52 1.00 1.07 0.96 1.02 155.16 6.74 -3.20
|
|
|
756 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 144 G 0.55 0.85 0.37 1.00 0.95 1.03 75.07 5.52 -0.40
|
|
|
757 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 145 I 0.56 0.31 0.54 0.99 0.95 1.02 131.17 5.52 4.50
|
|
|
758 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 146 G 0.56 0.39 1.06 0.96 0.94 1.02 75.07 5.52 -0.40
|
|
|
759 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 147 H 0.57 0.40 1.06 0.92 0.94 1.01 155.16 6.74 -3.20
|
|
|
760 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 148 I 0.59 0.40 -0.90 0.76 0.93 1.05 131.17 5.52 4.50
|
|
|
761 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 149 E 0.59 0.35 -1.07 0.78 0.92 1.04 147.13 4.00 -3.50
|
|
|
762 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 150 A 0.60 0.21 -3.20 0.64 0.92 1.10 89.09 5.57 1.80
|
|
|
763 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 151 I 0.62 0.60 -2.69 0.65 0.93 1.07 131.17 5.52 4.50
|
|
|
764 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 152 F 0.63 0.36 -2.97 0.72 0.94 1.03 165.19 5.52 2.80
|
|
|
765 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 153 L 0.64 0.49 -3.79 0.75 0.95 1.07 131.17 5.52 3.80
|
|
|
766 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 154 K 0.64 0.52 -4.61 0.73 0.95 1.11 146.19 8.75 -3.90
|
|
|
767 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 155 W 0.64 0.93 -3.17 0.88 0.96 1.10 204.23 5.52 -0.90
|
|
|
768 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 156 H 0.64 1.74 -1.56 1.01 0.96 1.10 155.16 6.74 -3.20
|
|
|
769 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 157 V 0.64 1.51 0.87 1.03 0.98 1.04 117.15 5.49 4.20
|
|
|
770 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 158 P 0.65 1.18 -1.26 0.97 1.00 1.09 115.13 5.96 -1.60
|
|
|
771 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 159 P 0.67 0.64 -0.36 0.90 1.01 1.16 115.13 5.96 -1.60
|
|
|
772 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 160 E 0.65 1.70 -0.06 0.90 1.00 1.12 147.13 4.00 -3.50
|
|
|
773 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 161 L 0.65 0.82 -0.06 0.90 0.98 1.12 131.17 5.52 3.80
|
|
|
774 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 162 V 0.63 0.44 -1.67 0.77 0.95 1.15 117.15 5.49 4.20
|
|
|
775 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 163 R 0.62 0.34 -1.04 0.76 0.94 1.14 174.20 9.75 -4.50
|
|
|
776 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 164 V 0.60 0.41 -1.86 0.75 0.93 1.17 117.15 5.49 4.20
|
|
|
777 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 165 L 0.58 0.55 -1.14 0.75 0.93 1.11 131.17 5.52 3.80
|
|
|
778 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 166 S 0.56 0.23 -1.93 0.76 0.92 1.09 105.09 5.24 -0.80
|
|
|
779 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 167 A 0.55 0.27 -3.84 0.71 0.91 1.13 89.09 5.57 1.80
|
|
|
780 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 168 M 0.52 0.27 -4.63 0.72 0.90 1.11 149.21 5.28 1.90
|
|
|
781 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 169 L 0.53 0.17 -4.63 0.72 0.90 1.11 131.17 5.52 3.80
|
|
|
782 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 170 F 0.53 0.12 -6.70 0.59 0.90 1.13 165.19 5.52 2.80
|
|
|
783 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 171 L 0.53 0.12 -6.19 0.71 0.91 1.10 131.17 5.52 3.80
|
|
|
784 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 172 L 0.55 0.07 -5.39 0.80 0.91 1.18 131.17 5.52 3.80
|
|
|
785 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 173 I 0.56 0.07 -5.39 0.80 0.91 1.18 131.17 5.52 4.50
|
|
|
786 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 174 G 0.56 0.07 -5.39 0.80 0.91 1.21 75.07 5.52 -0.40
|
|
|
787 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 175 C 0.55 0.07 -5.39 0.80 0.91 1.18 121.15 5.52 2.50
|
|
|
788 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 176 L 0.52 0.08 -4.60 0.79 0.91 1.20 131.17 5.52 3.80
|
|
|
789 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 177 L 0.49 0.07 -4.77 0.80 0.92 1.22 131.17 5.52 3.80
|
|
|
790 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 178 F 0.45 0.18 -4.84 0.72 0.93 1.22 165.19 5.52 2.80
|
|
|
791 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 179 V 0.43 0.33 -4.74 0.76 0.95 1.17 117.15 5.49 4.20
|
|
|
792 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 180 L 0.41 0.58 -2.69 0.82 0.98 1.12 131.17 5.52 3.80
|
|
|
793 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 181 T 0.39 0.58 -2.69 0.82 1.00 1.10 119.12 5.19 -0.70
|
|
|
794 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 182 P 0.39 0.58 -1.90 0.80 1.01 1.14 115.13 5.96 -1.60
|
|
|
795 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 183 T 0.39 0.61 -2.69 0.82 0.99 1.10 119.12 5.19 -0.70
|
|
|
796 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 184 F 0.41 0.23 -1.17 0.90 0.97 1.12 165.19 5.52 2.80
|
|
|
797 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 185 V 0.44 0.23 -2.19 0.93 0.94 1.16 117.15 5.49 4.20
|
|
|
798 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 186 F 0.47 0.16 -3.09 0.80 0.91 1.12 165.19 5.52 2.80
|
|
|
799 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 187 C 0.50 0.32 -2.71 0.77 0.90 1.12 121.15 5.52 2.50
|
|
|
800 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 188 Y 0.52 0.71 0.03 0.89 0.91 1.08 181.19 5.52 -1.30
|
|
|
801 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 189 M 0.54 0.87 -0.87 0.96 0.93 1.01 149.21 5.28 1.90
|
|
|
802 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 190 E 0.54 2.16 1.37 1.07 0.97 1.00 147.13 4.00 -3.50
|
|
|
803 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 191 D 0.53 2.76 1.99 1.05 1.00 0.93 133.10 3.80 -3.50
|
|
|
804 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 192 W 0.53 2.30 0.94 0.97 1.01 0.95 204.23 5.52 -0.90
|
|
|
805 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 193 S 0.51 2.30 2.66 0.99 1.02 0.95 105.09 5.24 -0.80
|
|
|
806 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 194 K 0.48 1.39 1.84 0.98 1.01 0.98 146.19 8.75 -3.90
|
|
|
807 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 195 L 0.45 0.93 -0.73 0.84 0.98 1.02 131.17 5.52 3.80
|
|
|
808 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 196 E 0.41 1.08 0.43 0.86 0.95 1.06 147.13 4.00 -3.50
|
|
|
809 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 197 A 0.37 0.47 -1.81 0.74 0.93 1.07 89.09 5.57 1.80
|
|
|
810 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 198 I 0.34 0.42 -3.16 0.67 0.90 1.14 131.17 5.52 4.50
|
|
|
811 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 199 Y 0.30 0.17 -2.99 0.65 0.89 1.12 181.19 5.52 -1.30
|
|
|
812 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 200 F 0.28 0.13 -4.63 0.62 0.89 1.20 165.19 5.52 2.80
|
|
|
813 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 201 V 0.25 0.26 -4.19 0.66 0.90 1.18 117.15 5.49 4.20
|
|
|
814 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 202 I 0.26 0.14 -4.36 0.68 0.91 1.19 131.17 5.52 4.50
|
|
|
815 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 203 V 0.26 0.23 -3.34 0.65 0.93 1.15 117.15 5.49 4.20
|
|
|
816 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 204 T 0.27 0.44 -1.29 0.71 0.95 1.13 119.12 5.19 -0.70
|
|
|
817 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 205 L 0.29 0.47 -1.29 0.71 0.98 1.13 131.17 5.52 3.80
|
|
|
818 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 206 T 0.32 0.62 0.67 0.86 1.00 1.09 119.12 5.19 -0.70
|
|
|
819 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 207 T 0.36 0.37 -0.11 0.88 1.00 1.05 119.12 5.19 -0.70
|
|
|
820 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 208 V 0.39 0.45 -0.04 0.96 0.99 1.04 117.15 5.49 4.20
|
|
|
821 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 209 G 0.42 0.52 2.70 1.09 0.98 0.99 75.07 5.52 -0.40
|
|
|
822 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 210 F 0.45 0.56 1.69 1.11 0.98 1.02 165.19 5.52 2.80
|
|
|
823 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 211 G 0.46 0.56 0.41 1.05 0.99 1.09 75.07 5.52 -0.40
|
|
|
824 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 212 D 0.48 0.58 1.24 1.07 0.99 1.04 133.10 3.80 -3.50
|
|
|
825 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 213 Y 0.49 0.66 1.24 1.07 0.97 1.04 181.19 5.52 -1.30
|
|
|
826 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 214 V 0.51 0.67 2.86 1.08 0.96 1.04 117.15 5.49 4.20
|
|
|
827 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 215 A 0.54 0.67 3.47 1.06 0.96 1.04 89.09 5.57 1.80
|
|
|
828 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 216 G 0.56 0.66 2.34 1.07 0.98 1.07 75.07 5.52 -0.40
|
|
|
829 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 217 A 0.58 1.75 3.21 1.04 1.01 1.03 89.09 5.57 1.80
|
|
|
830 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 218 D 0.59 3.00 4.60 1.11 1.04 0.97 133.10 3.80 -3.50
|
|
|
831 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 219 P 0.60 5.06 5.73 1.23 1.06 0.95 115.13 5.96 -1.60
|
|
|
832 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 220 R 0.63 6.71 5.84 1.21 1.08 0.97 174.20 9.75 -4.50
|
|
|
833 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 221 Q 0.64 6.21 5.84 1.33 1.09 0.97 146.15 5.52 -3.50
|
|
|
834 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 222 D 0.64 4.06 4.71 1.22 1.09 0.99 133.10 3.80 -3.50
|
|
|
835 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 223 S 0.63 3.25 4.14 1.16 1.08 1.01 105.09 5.24 -0.80
|
|
|
836 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 224 P 0.60 3.25 4.40 1.17 1.05 1.03 115.13 5.96 -1.60
|
|
|
837 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 225 A 0.57 3.01 3.84 1.24 1.02 1.04 89.09 5.57 1.80
|
|
|
838 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 226 Y 0.54 1.85 1.10 1.12 1.01 1.09 181.19 5.52 -1.30
|
|
|
839 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 227 Q 0.51 0.89 -0.36 0.99 1.00 1.14 146.15 5.52 -3.50
|
|
|
840 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 228 P 0.48 0.92 -2.09 0.91 0.98 1.12 115.13 5.96 -1.60
|
|
|
841 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 229 L 0.44 0.51 -3.70 0.90 0.96 1.12 131.17 5.52 3.80
|
|
|
842 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 230 V 0.40 0.31 -4.86 0.87 0.92 1.08 117.15 5.49 4.20
|
|
|
843 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 231 W 0.37 0.14 -6.86 0.80 0.89 1.10 204.23 5.52 -0.90
|
|
|
844 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 232 F 0.34 0.14 -8.47 0.67 0.87 1.13 165.19 5.52 2.80
|
|
|
845 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 233 W 0.31 0.16 -8.47 0.67 0.87 1.13 204.23 5.52 -0.90
|
|
|
846 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 234 I 0.29 0.15 -7.13 0.82 0.88 1.06 131.17 5.52 4.50
|
|
|
847 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 235 L 0.29 0.14 -7.01 0.77 0.91 1.11 131.17 5.52 3.80
|
|
|
848 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 236 L 0.30 0.13 -5.40 0.77 0.92 1.10 131.17 5.52 3.80
|
|
|
849 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 237 G 0.29 0.30 -4.24 0.80 0.92 1.14 75.07 5.52 -0.40
|
|
|
850 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 238 L 0.28 0.32 -4.41 0.82 0.92 1.13 131.17 5.52 3.80
|
|
|
851 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 239 A 0.29 0.39 -2.80 0.83 0.91 1.11 89.09 5.57 1.80
|
|
|
852 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 240 Y 0.29 0.52 -0.56 0.95 0.90 1.07 181.19 5.52 -1.30
|
|
|
853 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 241 F 0.30 0.47 -1.90 0.80 0.91 1.15 165.19 5.52 2.80
|
|
|
854 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 242 A 0.33 0.38 -1.90 0.80 0.92 1.15 89.09 5.57 1.80
|
|
|
855 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 243 S 0.35 0.35 -1.46 0.84 0.93 1.12 105.09 5.24 -0.80
|
|
|
856 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 244 V 0.35 0.59 -0.44 0.81 0.96 1.09 117.15 5.49 4.20
|
|
|
857 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 245 L 0.34 0.41 -0.27 0.80 0.98 1.10 131.17 5.52 3.80
|
|
|
858 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 246 T 0.36 0.30 0.24 0.92 1.00 1.07 119.12 5.19 -0.70
|
|
|
859 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 247 T 0.39 0.66 0.31 0.94 1.02 1.04 119.12 5.19 -0.70
|
|
|
860 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 248 I 0.40 0.84 -0.59 1.01 1.02 0.97 131.17 5.52 4.50
|
|
|
861 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 249 G 0.41 0.48 -0.59 1.01 1.01 0.97 75.07 5.52 -0.40
|
|
|
862 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 250 N 0.37 0.65 -0.73 1.01 0.00 0.96 132.12 5.52 -3.50
|
|
|
863 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 251 W 0.33 0.00 0.00 0.00 0.00 0.00 204.23 5.52 -0.90
|
|
|
864 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 252 L 0.28 0.00 0.00 0.00 0.00 0.00 131.17 5.52 3.80
|
|
|
865 4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation 253 R 0.24 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
866 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 1 C 0.24 0.00 0.00 0.00 0.00 0.00 121.15 5.52 2.50
|
|
|
867 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 2 D 0.29 0.00 0.00 0.00 0.00 0.00 133.10 3.80 -3.50
|
|
|
868 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 3 A 0.34 0.12 0.00 0.00 0.00 0.00 89.09 5.57 1.80
|
|
|
869 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 4 F 0.40 0.32 1.64 0.99 0.95 1.09 165.19 5.52 2.80
|
|
|
870 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 5 V 0.45 0.20 0.01 0.96 0.96 1.01 117.15 5.49 4.20
|
|
|
871 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 6 G 0.47 0.40 -0.60 0.89 0.99 1.02 75.07 5.52 -0.40
|
|
|
872 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 7 T 0.49 0.38 -2.21 0.88 1.00 1.05 119.12 5.19 -0.70
|
|
|
873 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 8 W 0.50 0.38 -1.43 0.87 0.99 1.09 204.23 5.52 -0.90
|
|
|
874 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 9 K 0.52 0.52 0.03 1.00 1.00 1.04 146.19 8.75 -3.90
|
|
|
875 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 10 L 0.53 0.48 0.14 0.98 1.00 1.06 131.17 5.52 3.80
|
|
|
876 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 11 V 0.55 0.79 0.51 0.95 1.01 1.05 117.15 5.49 4.20
|
|
|
877 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 12 S 0.56 0.64 2.94 1.04 1.04 1.03 105.09 5.24 -0.80
|
|
|
878 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 13 S 0.57 0.67 0.81 0.98 1.05 1.05 105.09 5.24 -0.80
|
|
|
879 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 14 E 0.58 1.51 3.56 1.10 1.05 1.00 147.13 4.00 -3.50
|
|
|
880 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 15 N 0.58 1.88 5.51 1.24 1.05 0.92 132.12 5.52 -3.50
|
|
|
881 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 16 F 0.55 2.20 4.31 1.20 1.03 0.95 165.19 5.52 2.80
|
|
|
882 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 17 D 0.55 1.26 2.79 1.08 1.02 0.92 133.10 3.80 -3.50
|
|
|
883 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 18 D 0.55 1.56 2.49 1.12 1.01 0.93 133.10 3.80 -3.50
|
|
|
884 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 19 Y 0.54 3.13 2.60 1.00 0.99 0.94 181.19 5.52 -1.30
|
|
|
885 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 20 M 0.53 1.39 3.39 0.99 0.99 0.98 149.21 5.28 1.90
|
|
|
886 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 21 K 0.53 0.82 2.77 1.00 0.99 0.98 146.19 8.75 -3.90
|
|
|
887 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 22 E 0.52 0.39 0.81 0.86 0.99 1.06 147.13 4.00 -3.50
|
|
|
888 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 23 V 0.53 0.39 1.90 0.92 0.98 1.02 117.15 5.49 4.20
|
|
|
889 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 24 G 0.54 0.17 1.19 0.92 0.97 1.06 75.07 5.52 -0.40
|
|
|
890 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 25 V 0.55 0.10 0.67 0.87 0.95 1.07 117.15 5.49 4.20
|
|
|
891 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 26 G 0.55 0.19 0.30 0.91 0.95 1.08 75.07 5.52 -0.40
|
|
|
892 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 27 F 0.54 0.38 1.43 0.97 0.96 1.01 165.19 5.52 2.80
|
|
|
893 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 28 A 0.54 1.02 1.43 0.89 0.98 1.02 89.09 5.57 1.80
|
|
|
894 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 29 T 0.52 0.77 1.43 0.89 1.00 1.02 119.12 5.19 -0.70
|
|
|
895 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 30 R 0.53 0.89 0.91 0.76 1.01 1.04 174.20 9.75 -4.50
|
|
|
896 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 31 K 0.52 0.88 3.04 0.90 1.01 1.01 146.19 8.75 -3.90
|
|
|
897 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 32 V 0.51 0.60 2.14 0.89 0.98 0.98 117.15 5.49 4.20
|
|
|
898 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 33 A 0.51 0.31 1.70 0.85 0.95 1.00 89.09 5.57 1.80
|
|
|
899 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 34 G 0.51 0.31 1.91 0.86 0.94 1.01 75.07 5.52 -0.40
|
|
|
900 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 35 M 0.50 0.65 1.40 0.93 0.94 1.03 149.21 5.28 1.90
|
|
|
901 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 36 A 0.48 1.03 2.93 1.08 0.97 0.94 89.09 5.57 1.80
|
|
|
902 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 37 K 0.47 1.03 2.03 1.07 0.99 0.91 146.19 8.75 -3.90
|
|
|
903 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 38 P 0.46 0.73 0.07 0.92 0.99 0.95 115.13 5.96 -1.60
|
|
|
904 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 39 N 0.45 0.50 -0.47 0.90 0.97 0.99 132.12 5.52 -3.50
|
|
|
905 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 40 M 0.45 0.34 0.16 1.01 0.94 0.99 149.21 5.28 1.90
|
|
|
906 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 41 I 0.45 0.16 -1.19 0.94 0.92 1.05 131.17 5.52 4.50
|
|
|
907 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 42 I 0.45 0.16 -0.49 0.94 0.92 1.01 131.17 5.52 4.50
|
|
|
908 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 43 S 0.46 0.16 -0.67 0.94 0.94 1.02 105.09 5.24 -0.80
|
|
|
909 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 44 V 0.47 0.39 1.36 1.06 0.98 1.03 117.15 5.49 4.20
|
|
|
910 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 45 N 0.47 0.46 1.19 1.08 1.02 1.04 132.12 5.52 -3.50
|
|
|
911 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 46 G 0.47 0.25 1.80 1.09 1.04 1.08 75.07 5.52 -0.40
|
|
|
912 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 47 D 0.47 0.49 1.61 1.02 1.03 1.06 133.10 3.80 -3.50
|
|
|
913 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 48 L 0.47 0.21 1.00 1.01 1.00 1.03 131.17 5.52 3.80
|
|
|
914 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 49 V 0.46 0.42 0.60 0.93 0.98 1.04 117.15 5.49 4.20
|
|
|
915 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 50 T 0.46 0.34 0.71 0.91 0.98 1.06 119.12 5.19 -0.70
|
|
|
916 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 51 I 0.45 0.71 0.40 0.81 1.01 1.06 131.17 5.52 4.50
|
|
|
917 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 52 R 0.45 1.29 2.64 0.93 1.05 1.03 174.20 9.75 -4.50
|
|
|
918 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 53 S 0.45 1.29 3.91 0.99 1.09 0.96 105.09 5.24 -0.80
|
|
|
919 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 54 E 0.47 1.59 1.86 0.94 1.09 0.99 147.13 4.00 -3.50
|
|
|
920 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 55 S 0.49 1.62 3.81 1.02 1.09 0.95 105.09 5.24 -0.80
|
|
|
921 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 56 T 0.50 1.95 4.21 1.10 1.07 0.94 119.12 5.19 -0.70
|
|
|
922 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 57 F 0.51 1.62 4.03 1.04 1.05 0.93 165.19 5.52 2.80
|
|
|
923 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 58 K 0.51 2.10 4.03 1.04 1.06 0.93 146.19 8.75 -3.90
|
|
|
924 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 59 N 0.50 1.02 1.96 0.90 1.06 0.95 132.12 5.52 -3.50
|
|
|
925 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 60 T 0.49 1.58 2.14 0.97 1.05 0.96 119.12 5.19 -0.70
|
|
|
926 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 61 E 0.48 0.68 2.14 0.97 1.03 0.96 147.13 4.00 -3.50
|
|
|
927 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 62 I 0.47 0.85 2.14 0.97 1.00 0.96 131.17 5.52 4.50
|
|
|
928 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 63 S 0.46 0.49 -0.17 0.83 0.98 1.03 105.09 5.24 -0.80
|
|
|
929 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 64 F 0.45 0.28 -0.10 0.91 0.97 1.02 165.19 5.52 2.80
|
|
|
930 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 65 K 0.46 0.29 -1.74 0.88 0.97 1.10 146.19 8.75 -3.90
|
|
|
931 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 66 L 0.46 0.38 0.51 0.92 0.97 1.06 131.17 5.52 3.80
|
|
|
932 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 67 G 0.47 0.38 -1.73 0.80 0.96 1.07 75.07 5.52 -0.40
|
|
|
933 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 68 V 0.49 0.32 1.01 0.92 0.96 1.04 117.15 5.49 4.20
|
|
|
934 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 69 E 0.52 0.67 1.31 0.88 0.97 1.02 147.13 4.00 -3.50
|
|
|
935 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 70 F 0.53 0.47 1.49 0.87 0.98 1.01 165.19 5.52 2.80
|
|
|
936 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 71 D 0.54 0.92 1.41 0.78 1.00 1.01 133.10 3.80 -3.50
|
|
|
937 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 72 E 0.56 0.53 2.24 0.80 1.01 0.97 147.13 4.00 -3.50
|
|
|
938 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 73 I 0.57 1.03 2.56 0.91 1.01 0.97 131.17 5.52 4.50
|
|
|
939 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 74 T 0.58 1.03 5.30 1.03 1.01 0.94 119.12 5.19 -0.70
|
|
|
940 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 75 A 0.59 1.17 4.47 0.96 1.02 0.94 89.09 5.57 1.80
|
|
|
941 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 76 D 0.58 3.33 4.17 1.00 1.04 0.95 133.10 3.80 -3.50
|
|
|
942 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 77 D 0.56 1.71 4.79 1.00 1.04 0.98 133.10 3.80 -3.50
|
|
|
943 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 78 R 0.54 3.39 4.86 1.01 1.05 0.99 174.20 9.75 -4.50
|
|
|
944 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 79 K 0.52 2.72 5.49 1.12 1.05 0.98 146.19 8.75 -3.90
|
|
|
945 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 80 V 0.49 1.14 2.91 0.98 1.03 1.02 117.15 5.49 4.20
|
|
|
946 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 81 K 0.48 0.41 0.34 0.83 1.02 1.06 146.19 8.75 -3.90
|
|
|
947 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 82 S 0.46 0.29 0.49 0.84 0.99 1.07 105.09 5.24 -0.80
|
|
|
948 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 83 I 0.43 0.33 -1.64 0.78 0.96 1.11 131.17 5.52 4.50
|
|
|
949 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 84 I 0.42 0.27 0.31 0.91 0.95 1.04 131.17 5.52 4.50
|
|
|
950 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 85 T 0.43 0.20 0.31 0.99 0.97 1.03 119.12 5.19 -0.70
|
|
|
951 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 86 L 0.43 0.28 0.20 1.01 1.00 1.01 131.17 5.52 3.80
|
|
|
952 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 87 D 0.43 0.41 1.64 1.04 1.03 1.00 133.10 3.80 -3.50
|
|
|
953 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 88 G 0.44 0.23 1.47 1.05 1.04 1.01 75.07 5.52 -0.40
|
|
|
954 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 89 G 0.46 0.21 0.20 0.99 1.02 1.08 75.07 5.52 -0.40
|
|
|
955 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 90 A 0.46 0.22 2.37 1.04 0.99 1.05 89.09 5.57 1.80
|
|
|
956 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 91 L 0.47 0.16 0.41 0.91 0.96 1.12 131.17 5.52 3.80
|
|
|
957 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 92 V 0.49 0.29 0.46 0.82 0.94 1.14 117.15 5.49 4.20
|
|
|
958 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 93 Q 0.50 0.57 0.46 0.75 0.95 1.15 146.15 5.52 -3.50
|
|
|
959 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 94 V 0.52 0.73 -1.27 0.79 0.97 1.12 117.15 5.49 4.20
|
|
|
960 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 95 Q 0.53 1.63 1.47 0.91 1.00 1.07 146.15 5.52 -3.50
|
|
|
961 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 96 K 0.54 0.93 2.81 1.06 1.02 1.00 146.19 8.75 -3.90
|
|
|
962 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 97 W 0.55 2.51 2.77 1.07 1.04 0.98 204.23 5.52 -0.90
|
|
|
963 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 98 D 0.55 1.94 4.23 1.20 1.07 0.93 133.10 3.80 -3.50
|
|
|
964 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 99 G 0.56 1.40 4.11 1.20 1.09 0.92 75.07 5.52 -0.40
|
|
|
965 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 100 K 0.55 1.93 4.04 1.19 1.10 0.91 146.19 8.75 -3.90
|
|
|
966 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 101 S 0.55 0.81 4.33 1.12 1.10 0.95 105.09 5.24 -0.80
|
|
|
967 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 102 T 0.54 1.63 3.71 1.06 1.09 0.96 119.12 5.19 -0.70
|
|
|
968 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 103 T 0.53 1.60 3.50 0.97 1.07 0.96 119.12 5.19 -0.70
|
|
|
969 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 104 I 0.52 2.39 3.50 0.97 1.06 0.96 131.17 5.52 4.50
|
|
|
970 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 105 K 0.52 3.24 3.17 0.90 1.05 0.94 146.19 8.75 -3.90
|
|
|
971 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 106 R 0.51 3.75 3.86 0.97 1.05 0.93 174.20 9.75 -4.50
|
|
|
972 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 107 K 0.51 5.29 3.93 1.06 1.06 0.93 146.19 8.75 -3.90
|
|
|
973 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 108 R 0.51 4.42 6.50 1.20 1.06 0.89 174.20 9.75 -4.50
|
|
|
974 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 109 D 0.50 4.51 6.50 1.20 1.07 0.89 133.10 3.80 -3.50
|
|
|
975 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 110 G 0.49 1.86 4.59 1.15 1.07 0.94 75.07 5.52 -0.40
|
|
|
976 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 111 D 0.47 0.71 3.24 1.08 1.05 1.01 133.10 3.80 -3.50
|
|
|
977 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 112 K 0.46 0.31 2.11 1.01 1.02 1.08 146.19 8.75 -3.90
|
|
|
978 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 113 L 0.44 0.55 1.80 0.91 0.99 1.08 131.17 5.52 3.80
|
|
|
979 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 114 V 0.43 0.18 1.19 0.86 0.95 1.15 117.15 5.49 4.20
|
|
|
980 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 115 V 0.43 0.07 -0.77 0.72 0.93 1.23 117.15 5.49 4.20
|
|
|
981 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 116 E 0.43 0.08 -2.19 0.66 0.91 1.21 147.13 4.00 -3.50
|
|
|
982 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 117 C 0.42 0.21 -0.06 0.72 0.91 1.17 121.15 5.52 2.50
|
|
|
983 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 118 V 0.41 0.28 1.29 0.87 0.93 1.09 117.15 5.49 4.20
|
|
|
984 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 119 M 0.42 0.12 1.29 0.87 0.95 1.09 149.21 5.28 1.90
|
|
|
985 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 120 K 0.42 0.33 0.91 0.90 0.98 1.10 146.19 8.75 -3.90
|
|
|
986 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 121 G 0.43 0.59 1.64 0.94 1.02 1.05 75.07 5.52 -0.40
|
|
|
987 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 122 V 0.45 0.86 2.91 1.00 1.04 0.98 117.15 5.49 4.20
|
|
|
988 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 123 T 0.44 0.84 4.11 1.05 1.06 0.98 119.12 5.19 -0.70
|
|
|
989 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 124 S 0.44 0.63 2.77 0.98 1.06 1.05 105.09 5.24 -0.80
|
|
|
990 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 125 T 0.44 1.33 1.69 0.92 1.05 1.09 119.12 5.19 -0.70
|
|
|
991 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 126 R 0.45 1.59 3.33 0.95 1.02 1.01 174.20 9.75 -4.50
|
|
|
992 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 127 V 0.45 2.33 3.19 0.95 1.00 1.01 117.15 5.49 4.20
|
|
|
993 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 128 Y 0.40 1.63 2.56 0.84 0.00 1.02 181.19 5.52 -1.30
|
|
|
994 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 129 E 0.35 0.00 0.00 0.00 0.00 0.00 147.13 4.00 -3.50
|
|
|
995 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 130 R 0.31 0.00 0.00 0.00 0.00 0.00 174.20 9.75 -4.50
|
|
|
996 5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. 131 A 0.25 0.00 0.00 0.00 0.00 0.00 89.09 5.57 1.80
|
|
|
997 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 1 L 0.26 0.00 0.00 0.00 0.00 0.00 131.17 5.52 3.80
|
|
|
998 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 2 G 0.31 0.00 0.00 0.00 0.00 0.00 75.07 5.52 -0.40
|
|
|
999 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 3 S 0.37 1.28 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
1000 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 4 R 0.43 1.28 1.06 1.00 1.06 1.01 174.20 9.75 -4.50
|
|
|
1001 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 5 R 0.48 1.28 1.77 1.01 1.03 0.95 174.20 9.75 -4.50
|
|
|
1002 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 6 T 0.46 0.79 -0.36 0.87 1.00 1.00 119.12 5.19 -0.70
|
|
|
1003 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 7 L 0.47 0.33 -2.60 0.75 0.96 1.03 131.17 5.52 3.80
|
|
|
1004 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 8 M 0.47 0.17 -2.90 0.71 0.92 1.06 149.21 5.28 1.90
|
|
|
1005 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 9 L 0.44 0.21 -2.64 0.71 0.91 1.08 131.17 5.52 3.80
|
|
|
1006 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 10 L 0.46 0.25 -3.99 0.66 0.91 1.07 131.17 5.52 3.80
|
|
|
1007 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 11 A 0.47 0.49 -2.07 0.71 0.92 1.01 89.09 5.57 1.80
|
|
|
1008 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 12 Q 0.48 1.18 -0.66 0.77 0.94 1.03 146.15 5.52 -3.50
|
|
|
1009 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 13 M 0.49 1.01 -0.49 0.75 0.97 1.02 149.21 5.28 1.90
|
|
|
1010 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 14 R 0.51 1.33 1.76 0.87 0.99 0.98 174.20 9.75 -4.50
|
|
|
1011 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 15 K 0.54 0.64 0.14 0.86 1.00 1.01 146.19 8.75 -3.90
|
|
|
1012 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 16 I 0.55 0.56 -2.03 0.81 0.99 1.02 131.17 5.52 4.50
|
|
|
1013 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 17 S 0.55 0.38 -0.50 0.93 0.97 1.05 105.09 5.24 -0.80
|
|
|
1014 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 18 L 0.59 0.10 -0.90 0.96 0.95 1.12 131.17 5.52 3.80
|
|
|
1015 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 19 F 0.58 0.12 -3.03 0.90 0.93 1.17 165.19 5.52 2.80
|
|
|
1016 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 20 S 0.57 0.18 -1.07 0.98 0.93 1.14 105.09 5.24 -0.80
|
|
|
1017 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 21 C 0.57 0.36 -0.57 0.98 0.95 1.12 121.15 5.52 2.50
|
|
|
1018 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 22 L 0.58 0.82 1.34 1.03 0.97 1.06 131.17 5.52 3.80
|
|
|
1019 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 23 K 0.58 0.83 2.96 1.08 1.00 1.06 146.19 8.75 -3.90
|
|
|
1020 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 24 D 0.56 2.59 3.46 1.09 1.01 1.04 133.10 3.80 -3.50
|
|
|
1021 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 25 R 0.57 2.72 1.94 1.00 1.00 1.00 174.20 9.75 -4.50
|
|
|
1022 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 26 H 0.57 1.35 4.07 1.14 0.98 0.94 155.16 6.74 -3.20
|
|
|
1023 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 27 D 0.56 0.70 1.94 1.08 0.96 0.97 133.10 3.80 -3.50
|
|
|
1024 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 28 F 0.55 0.55 0.81 1.09 0.95 0.99 165.19 5.52 2.80
|
|
|
1025 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 29 G 0.55 0.70 1.07 1.10 0.97 1.02 75.07 5.52 -0.40
|
|
|
1026 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 30 F 0.54 0.73 1.89 1.07 1.00 0.98 165.19 5.52 2.80
|
|
|
1027 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 31 P 0.53 1.46 1.57 0.96 1.04 0.98 115.13 5.96 -1.60
|
|
|
1028 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 32 Q 0.54 1.27 1.57 0.96 1.06 0.98 146.15 5.52 -3.50
|
|
|
1029 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 33 E 0.55 1.46 1.57 0.96 1.06 0.98 147.13 4.00 -3.50
|
|
|
1030 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 34 E 0.56 1.52 3.89 1.10 1.05 0.93 147.13 4.00 -3.50
|
|
|
1031 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 35 F 0.58 1.52 4.44 1.02 1.04 0.92 165.19 5.52 2.80
|
|
|
1032 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 36 G 0.60 0.76 2.27 0.97 1.03 0.94 75.07 5.52 -0.40
|
|
|
1033 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 37 N 0.60 0.76 2.01 1.00 1.03 0.96 132.12 5.52 -3.50
|
|
|
1034 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 38 Q 0.61 1.75 1.71 1.04 1.03 0.97 146.15 5.52 -3.50
|
|
|
1035 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 39 F 0.61 1.79 3.33 1.05 1.02 0.97 165.19 5.52 2.80
|
|
|
1036 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 40 Q 0.60 1.92 3.63 0.93 1.03 0.96 146.15 5.52 -3.50
|
|
|
1037 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 41 K 0.57 1.60 3.37 0.85 1.03 0.98 146.19 8.75 -3.90
|
|
|
1038 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 42 A 0.55 1.30 1.37 0.77 1.04 1.00 89.09 5.57 1.80
|
|
|
1039 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 43 E 0.51 1.16 2.99 0.91 1.03 1.00 147.13 4.00 -3.50
|
|
|
1040 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 44 T 0.46 0.43 1.60 0.84 1.02 1.05 119.12 5.19 -0.70
|
|
|
1041 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 45 I 0.44 0.35 -0.53 0.78 0.99 1.10 131.17 5.52 4.50
|
|
|
1042 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 46 P 0.41 0.28 -0.53 0.82 0.97 1.10 115.13 5.96 -1.60
|
|
|
1043 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 47 V 0.38 0.33 -0.53 0.82 0.95 1.10 117.15 5.49 4.20
|
|
|
1044 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 48 L 0.35 0.47 -1.87 0.77 0.93 1.09 131.17 5.52 3.80
|
|
|
1045 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 49 H 0.34 0.21 -1.87 0.77 0.92 1.09 155.16 6.74 -3.20
|
|
|
1046 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 50 E 0.35 0.49 -1.31 0.69 0.92 1.08 147.13 4.00 -3.50
|
|
|
1047 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 51 M 0.34 1.04 0.07 0.76 0.93 1.03 149.21 5.28 1.90
|
|
|
1048 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 52 I 0.36 0.53 0.24 0.74 0.94 1.02 131.17 5.52 4.50
|
|
|
1049 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 53 Q 0.39 0.27 -1.37 0.69 0.95 1.01 146.15 5.52 -3.50
|
|
|
1050 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 54 Q 0.38 0.43 -1.49 0.81 0.95 1.00 146.15 5.52 -3.50
|
|
|
1051 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 55 I 0.38 0.51 -2.20 0.81 0.95 1.06 131.17 5.52 4.50
|
|
|
1052 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 56 F 0.41 0.26 -2.37 0.83 0.94 1.06 165.19 5.52 2.80
|
|
|
1053 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 57 N 0.44 0.20 -2.30 0.89 0.94 1.06 132.12 5.52 -3.50
|
|
|
1054 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 58 L 0.46 0.41 -2.41 0.89 0.95 1.04 131.17 5.52 3.80
|
|
|
1055 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 59 F 0.49 0.94 -0.46 0.96 0.98 1.01 165.19 5.52 2.80
|
|
|
1056 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 60 S 0.54 0.98 2.29 1.09 1.01 0.98 105.09 5.24 -0.80
|
|
|
1057 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 61 T 0.56 1.59 2.21 1.07 1.05 1.01 119.12 5.19 -0.70
|
|
|
1058 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 62 K 0.58 2.46 4.46 1.19 1.07 0.98 146.19 8.75 -3.90
|
|
|
1059 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 63 D 0.60 1.85 6.07 1.20 1.07 0.97 133.10 3.80 -3.50
|
|
|
1060 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 64 S 0.62 1.30 5.44 1.09 1.06 0.98 105.09 5.24 -0.80
|
|
|
1061 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 65 S 0.62 0.68 3.27 1.09 1.02 0.98 105.09 5.24 -0.80
|
|
|
1062 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 66 A 0.63 0.68 3.89 1.15 0.99 0.97 89.09 5.57 1.80
|
|
|
1063 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 67 A 0.62 0.88 3.57 1.05 0.98 0.97 89.09 5.57 1.80
|
|
|
1064 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 68 W 0.59 0.95 3.39 0.98 0.99 0.95 204.23 5.52 -0.90
|
|
|
1065 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 69 D 0.56 0.77 1.14 0.86 1.01 0.99 133.10 3.80 -3.50
|
|
|
1066 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 70 E 0.53 0.63 -0.47 0.85 1.03 1.01 147.13 4.00 -3.50
|
|
|
1067 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 71 T 0.52 1.00 0.66 0.97 1.03 0.98 119.12 5.19 -0.70
|
|
|
1068 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 72 L 0.48 1.20 2.90 0.97 1.03 0.99 131.17 5.52 3.80
|
|
|
1069 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 73 L 0.48 0.60 0.16 0.85 1.02 1.02 131.17 5.52 3.80
|
|
|
1070 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 74 D 0.47 0.65 -1.23 0.91 1.01 1.07 133.10 3.80 -3.50
|
|
|
1071 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 75 K 0.45 1.14 -1.23 0.91 1.01 1.07 146.19 8.75 -3.90
|
|
|
1072 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 76 F 0.42 2.40 1.20 0.93 1.00 1.01 165.19 5.52 2.80
|
|
|
1073 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 77 Y 0.43 1.18 1.20 0.93 0.99 1.01 181.19 5.52 -1.30
|
|
|
1074 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 78 T 0.44 0.93 -0.50 0.88 0.99 1.05 119.12 5.19 -0.70
|
|
|
1075 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 79 E 0.44 1.85 -0.46 0.88 0.99 1.06 147.13 4.00 -3.50
|
|
|
1076 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 80 L 0.43 2.05 1.71 0.93 0.99 1.05 131.17 5.52 3.80
|
|
|
1077 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 81 Y 0.46 1.17 0.67 0.85 0.99 1.06 181.19 5.52 -1.30
|
|
|
1078 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 82 Q 0.47 1.09 0.93 0.94 0.99 1.05 146.15 5.52 -3.50
|
|
|
1079 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 83 Q 0.46 2.20 1.24 1.04 1.00 1.05 146.15 5.52 -3.50
|
|
|
1080 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 84 L 0.48 1.16 1.24 1.04 1.01 1.05 131.17 5.52 3.80
|
|
|
1081 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 85 N 0.51 1.16 2.63 0.99 1.01 1.00 132.12 5.52 -3.50
|
|
|
1082 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 86 D 0.48 0.68 2.07 0.94 1.00 1.01 133.10 3.80 -3.50
|
|
|
1083 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 87 L 0.48 0.44 1.41 0.97 0.98 1.07 131.17 5.52 3.80
|
|
|
1084 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 88 E 0.48 0.20 2.20 0.96 0.96 1.09 147.13 4.00 -3.50
|
|
|
1085 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 89 A 0.50 0.09 0.06 0.80 0.94 1.14 89.09 5.57 1.80
|
|
|
1086 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 90 C 0.50 0.18 -0.51 0.73 0.93 1.16 121.15 5.52 2.50
|
|
|
1087 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 91 V 0.51 0.10 1.61 0.87 0.94 1.11 117.15 5.49 4.20
|
|
|
1088 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 92 I 0.54 0.10 -0.10 0.85 0.95 1.10 131.17 5.52 4.50
|
|
|
1089 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 93 Q 0.53 0.37 0.41 0.90 0.98 1.08 146.15 5.52 -3.50
|
|
|
1090 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 94 G 0.54 0.87 1.33 0.84 1.00 1.00 75.07 5.52 -0.40
|
|
|
1091 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 95 M 0.56 2.08 3.29 0.97 1.02 0.93 149.21 5.28 1.90
|
|
|
1092 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 96 K 0.57 1.61 5.36 1.11 1.04 0.91 146.19 8.75 -3.90
|
|
|
1093 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 97 E 0.57 1.14 3.36 1.04 1.04 0.93 147.13 4.00 -3.50
|
|
|
1094 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 98 D 0.56 0.95 1.23 0.90 1.02 0.98 133.10 3.80 -3.50
|
|
|
1095 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 99 S 0.53 0.48 2.13 0.91 1.00 1.02 105.09 5.24 -0.80
|
|
|
1096 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 100 I 0.52 0.21 0.79 0.84 0.96 1.08 131.17 5.52 4.50
|
|
|
1097 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 101 L 0.53 0.24 0.27 0.87 0.94 1.09 131.17 5.52 3.80
|
|
|
1098 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 102 A 0.51 0.36 -0.34 0.80 0.94 1.09 89.09 5.57 1.80
|
|
|
1099 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 103 V 0.49 0.80 -1.54 0.76 0.96 1.12 117.15 5.49 4.20
|
|
|
1100 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 104 R 0.48 0.84 -1.71 0.78 0.98 1.11 174.20 9.75 -4.50
|
|
|
1101 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 105 K 0.48 1.45 0.46 0.83 0.99 1.07 146.19 8.75 -3.90
|
|
|
1102 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 106 Y 0.46 3.82 0.76 0.88 0.99 1.05 181.19 5.52 -1.30
|
|
|
1103 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 107 F 0.46 1.37 0.14 0.87 0.99 1.01 165.19 5.52 2.80
|
|
|
1104 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 108 Q 0.49 0.99 0.29 0.87 0.99 1.02 146.15 5.52 -3.50
|
|
|
1105 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 109 R 0.48 0.52 -1.84 0.81 0.99 1.06 174.20 9.75 -4.50
|
|
|
1106 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 110 I 0.44 0.94 -1.84 0.81 0.98 1.06 131.17 5.52 4.50
|
|
|
1107 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 111 T 0.44 0.45 -1.84 0.81 0.96 1.09 119.12 5.19 -0.70
|
|
|
1108 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 112 L 0.47 0.46 -1.89 0.82 0.95 1.08 131.17 5.52 3.80
|
|
|
1109 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 113 Y 0.48 1.13 -1.37 0.79 0.95 1.07 181.19 5.52 -1.30
|
|
|
1110 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 114 L 0.47 1.56 0.59 0.86 0.98 1.04 131.17 5.52 3.80
|
|
|
1111 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 115 K 0.50 3.79 0.66 0.87 1.02 1.04 146.19 8.75 -3.90
|
|
|
1112 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 116 E 0.49 3.79 1.70 0.95 1.05 1.03 147.13 4.00 -3.50
|
|
|
1113 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 117 K 0.48 6.16 2.90 0.99 1.06 1.01 146.19 8.75 -3.90
|
|
|
1114 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 118 K 0.48 4.76 4.51 1.12 1.06 0.98 146.19 8.75 -3.90
|
|
|
1115 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 119 Y 0.49 1.47 3.90 1.15 1.04 1.05 181.19 5.52 -1.30
|
|
|
1116 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 120 S 0.48 0.74 3.09 1.14 1.01 1.08 105.09 5.24 -0.80
|
|
|
1117 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 121 P 0.46 0.39 0.84 1.13 0.99 1.08 115.13 5.96 -1.60
|
|
|
1118 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 122 C 0.45 0.43 1.14 1.09 0.95 1.07 121.15 5.52 2.50
|
|
|
1119 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 123 A 0.41 0.24 0.89 1.00 0.94 1.10 89.09 5.57 1.80
|
|
|
1120 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 124 W 0.40 0.11 -0.57 0.87 0.92 1.15 204.23 5.52 -0.90
|
|
|
1121 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 125 E 0.39 0.42 -0.27 0.79 0.92 1.12 147.13 4.00 -3.50
|
|
|
1122 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 126 V 0.38 0.42 -0.17 0.71 0.93 1.07 117.15 5.49 4.20
|
|
|
1123 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 127 V 0.36 0.69 0.64 0.72 0.94 1.04 117.15 5.49 4.20
|
|
|
1124 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 128 R 0.39 0.28 0.93 0.65 0.94 1.08 174.20 9.75 -4.50
|
|
|
1125 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 129 A 0.40 0.37 -0.79 0.63 0.94 1.08 89.09 5.57 1.80
|
|
|
1126 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 130 E 0.39 0.99 0.34 0.70 0.94 1.00 147.13 4.00 -3.50
|
|
|
1127 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 131 I 0.37 0.67 1.80 0.83 0.94 0.95 131.17 5.52 4.50
|
|
|
1128 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 132 M 0.40 0.58 -0.11 0.78 0.95 0.98 149.21 5.28 1.90
|
|
|
1129 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 133 R 0.41 0.45 0.51 0.89 0.96 0.97 174.20 9.75 -4.50
|
|
|
1130 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 134 S 0.41 0.53 -1.91 0.87 0.97 1.03 105.09 5.24 -0.80
|
|
|
1131 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 135 F 0.42 0.71 0.16 1.00 0.97 1.01 165.19 5.52 2.80
|
|
|
1132 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 136 S 0.45 0.52 1.50 1.06 0.98 1.02 105.09 5.24 -0.80
|
|
|
1133 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 137 L 0.43 0.63 1.90 1.14 0.99 1.01 131.17 5.52 3.80
|
|
|
1134 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 138 S 0.43 0.60 -0.34 1.02 1.00 1.04 105.09 5.24 -0.80
|
|
|
1135 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 139 T 0.45 0.78 1.83 1.08 1.02 1.03 119.12 5.19 -0.70
|
|
|
1136 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 140 N 0.47 1.63 2.01 0.98 1.02 1.01 132.12 5.52 -3.50
|
|
|
1137 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 141 L 0.45 1.63 4.26 1.10 1.02 0.97 131.17 5.52 3.80
|
|
|
1138 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 142 Q 0.39 0.93 2.01 0.98 0.00 1.01 146.15 5.52 -3.50
|
|
|
1139 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 143 E 0.36 0.00 0.00 0.00 0.00 0.00 147.13 4.00 -3.50
|
|
|
1140 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 144 S 0.29 0.00 0.00 0.00 0.00 0.00 105.09 5.24 -0.80
|
|
|
1141 4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2 145 L 0.24 0.00 0.00 0.00 0.00 0.00 131.17 5.52 3.80
|
